1 January 2016 CURRICULUM VITAE MICHAEL ROSENBLATT, M.D. Brief Biographical Sketch: Dr. Rosenblatt is Executive Vice President and Chief Medical Officer of Merck & Co., Inc. He is the first person to serve in this role for Merck. Previously he served as Dean of Tufts University School of Medicine. Prior to that, he held the appointment of George R. Minot Professor of Medicine at Harvard Medical School. He served as the President of Beth Israel Deaconess Medical Center (BIDMC) from 1999-2001. Previously, he was the Harvard Faculty Dean and Senior Vice President for Academic Programs at BIDMC. Prior to that, he served as Director of the Harvard-MIT Division of Health Sciences and Technology, during which time he led a medical education organization for M.D., Ph.D., and M.D.- Ph.D. training jointly sponsored by Harvard and MIT. And earlier, he was Senior Vice President for Research at Merck Research Laboratories where he co-led the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis and bone disorders. In addition, he directed drug discovery efforts in molecular biology, bone biology and calcium metabolism, virology, cancer research, lipid metabolism, and cardiovascular research in the United States, Japan, and Italy. He also headed Merck Research's worldwide University and Industry Relations Department. He is the recipient of the Fuller Albright Award for his work on parathyroid hormone and the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman’s Award from Merck. His major research has been in parathyroid hormone-receptor interactions, elucidating the mechanisms by which breast cancer “homes” to bone, and osteoporosis and bone biology. He has been an active participant in the biotechnology industry, serving on the board of directors and scientific advisory boards of several biotech companies. He was a scientific founder of ProScript, the company that discovered bortezomib (Velcade), now Millennium Pharmaceutical’s drug for multiple myeloma and other malignancies, and Radius Pharmaceuticals, a women’s health company. He was a member of the Board of Scientific Counselors of the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians, to Fellowship in the American Association for the Advancement of Science and the American College of Physicians, and the presidency of the American Society of Bone and Mineral Research. He has testified before a Senate Hearing on U.S. biomedical research priorities in 1997, and in 2011 as a consultant to the U.S. President's Council of Advisors on Science and Technology. He currently is a member of the Harvard Medical School Board of Fellows, and the research advisory committees of the Massachusetts General Hospital, the Brigham and Women’s Hospital and the National Health Council. From 1981 to 1984, he served as Chief of the Endocrine Unit, Massachusetts General Hospital. He received his undergraduate degree summa cum laude from Columbia and his M.D. magna cum laude from Harvard. His internship, residency, and endocrinology training were all at the Massachusetts General Hospital.
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
1
January 2016 CURRICULUM VITAE
MICHAEL ROSENBLATT, M.D.
Brief Biographical Sketch:
Dr. Rosenblatt is Executive Vice President and Chief Medical Officer of Merck & Co., Inc. He is the first person to serve in this role for Merck. Previously he served as Dean of Tufts University School of Medicine. Prior to that, he held the appointment of George R. Minot Professor of Medicine at Harvard Medical School. He served as the President of Beth Israel Deaconess Medical Center (BIDMC) from 1999-2001. Previously, he was the Harvard Faculty Dean and Senior Vice President for Academic Programs at BIDMC.
Prior to that, he served as Director of the Harvard-MIT Division of Health Sciences and
Technology, during which time he led a medical education organization for M.D., Ph.D., and M.D.-Ph.D. training jointly sponsored by Harvard and MIT. And earlier, he was Senior Vice President for Research at Merck Research Laboratories where he co-led the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis and bone disorders. In addition, he directed drug discovery efforts in molecular biology, bone biology and calcium metabolism, virology, cancer research, lipid metabolism, and cardiovascular research in the United States, Japan, and Italy. He also headed Merck Research's worldwide University and Industry Relations Department.
He is the recipient of the Fuller Albright Award for his work on parathyroid hormone and the
Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman’s Award from Merck. His major research has been in parathyroid hormone-receptor interactions, elucidating the mechanisms by which breast cancer “homes” to bone, and osteoporosis and bone biology.
He has been an active participant in the biotechnology industry, serving on the board of
directors and scientific advisory boards of several biotech companies. He was a scientific founder of ProScript, the company that discovered bortezomib (Velcade), now Millennium Pharmaceutical’s drug for multiple myeloma and other malignancies, and Radius Pharmaceuticals, a women’s health company. He was a member of the Board of Scientific Counselors of the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians, to Fellowship in the American Association for the Advancement of Science and the American College of Physicians, and the presidency of the American Society of Bone and Mineral Research. He has testified before a Senate Hearing on U.S. biomedical research priorities in 1997, and in 2011 as a consultant to the U.S. President's Council of Advisors on Science and Technology.
He currently is a member of the Harvard Medical School Board of Fellows, and the research
advisory committees of the Massachusetts General Hospital, the Brigham and Women’s Hospital and the National Health Council.
From 1981 to 1984, he served as Chief of the Endocrine Unit, Massachusetts General
Hospital. He received his undergraduate degree summa cum laude from Columbia and his M.D. magna cum laude from Harvard. His internship, residency, and endocrinology training were all at the Massachusetts General Hospital.
2
January 2016 MICHAEL ROSENBLATT, M.D. Executive Vice President and Chief Medical Officer Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth, NJ 07033 Tel 908-740-1160 Fax 908.740-1593 [email protected] Place of Birth: Lund, Sweden Citizenship: USA Education:
1969 A.B. Summa cum laude, Columbia College, New York, New York 1973 M.D. Magna cum laude, Harvard Medical School, Boston, Massachusetts
Postdoctoral Training:
Internships and Residencies: 1973-74 Intern in Medicine, Massachusetts General Hospital, Boston, Massachusetts (Dr.
Alexander Leaf, Chief) 1974-75 Assistant Resident in Medicine, Massachusetts General Hospital, Boston,
Massachusetts (Dr. Alexander Leaf, Chief) Research Fellowships: 1975-76 Research Fellow in Medicine, Harvard Medical School, Boston, Massachusetts 1975-77 Clinical and Research Fellow in Medicine (Endocrinology), (Dr. John T. Potts, Jr.,
Chief), Massachusetts General Hospital, Boston, Massachusetts
Licensure and Certification:
1974- Massachusetts Board of Registration in Medicine (MA-37320) 1976 American Board of Internal Medicine 1977 American Board of Internal Medicine: Endocrinology and Metabolism
3
Academic Appointments:
1976-78 Instructor in Medicine, Harvard Medical School, Boston, Massachusetts 1976 Visiting Scientist, Howard Florey Institute of Experimental Medicine and
Physiology, Melbourne, Australia 1978-82 Assistant Professor of Medicine, Harvard Medical School 1981-84 Chief, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 1982-85 Associate Professor of Medicine, Massachusetts General Hospital, Harvard
Medical School 1985-88 Adjunct Associate Professor of Medicine, University of Pennsylvania School of
Medicine, Philadelphia, Pennsylvania 1985-91 Lecturer on Medicine, Harvard Medical School 1988- Adjunct Professor of Medicine, University of Pennsylvania School of Medicine 1992-98 Master, Health Science and Technology Society, Harvard Medical School 1992-98 Robert H. Ebert Professor of Molecular Medicine, Harvard Medical School 1992-98 Director, Harvard-MIT Division of Health Sciences and Technology (HST),
Cambridge and Boston, Massachusetts 1993- Faculty Member, Department of Biological Chemistry and Molecular
Pharmacology, Biological and Biomedical Sciences Program, Division of Medical Sciences, Harvard University
1996-2000 Executive Director, Carl J. Shapiro Institute for Education and Research at Harvard Medical School and Beth Israel Deaconess Medical Center
1996-2000 Harvard Faculty Dean for Academic Programs at Beth Israel Deaconess Medical Center and CareGroup, Boston, Massachusetts
1998-2003 George R. Minot Professor of Medicine, Harvard Medical School 2001-02 Visiting Scientist, The Whitehead Institute, Massachusetts Institute of Technology
(laboratory of Dr. Robert A. Weinberg) 2002 Visiting Scientist, Children’s Hospital, Boston, (laboratory of Dr. Bruce Zetter) 2002-03 Chief, Division of Bone and Mineral Metabolism Research, Beth Israel Deaconess
Medical Center 2003-09 Member, Cellular and Molecular Physiology program, Sackler School of Graduate
Biomedical Studies, Boston, Massachusetts 2003-10 Professor of Physiology, Tufts University School of Medicine, Boston,
Massachusetts 2003 Professor of Medicine, Tufts University School of Medicine, Boston, Massachusetts 2003-09 Member, Integrated Studies Program, Sackler School of Graduate Biomedical
Sciences 2003-09 Dean, Tufts University School of Medicine 2011- Adjunct Professor, Department of Medicine, Tufts University School of Medicine 2012- Adjunct Professor of Medicine in the Associated Faculty of the Perelman School of
Medicine
Hospital Appointments:
1978-84 Clinical Director, Endocrine Associates, Group Practice, Massachusetts General Hospital, Boston, Massachusetts
1981-84 Chief, Endocrine Unit, Massachusetts General Hospital 1984-92 Consultant in Medicine, Massachusetts General Hospital 1985-92 Staff Physician, Hospital of the University of Pennsylvania (Endocrine Group),
Philadelphia, Pennsylvania
4
1992-2000 Chief, Division of Bone and Mineral Metabolism, Beth Israel Hospital, Boston, Massachusetts
1993- Honorary Physician, Massachusetts General Hospital 1996-2000 Executive Director, Carl J. Shapiro Institute for Education and Research at Harvard
Medical School and Beth Israel Deaconess Mount Auburn 1996-2000 Senior Vice President for Academic Affairs, Beth Israel Deaconess Medical Center
and CareGroup, Boston, Massachusetts 1999-2001 President, Beth Israel Deaconess Medical Center, Boston, Massachusetts 2003- Physician Staff, Division of Endocrinology, Department of Medicine, Tufts-New
England Medical Center, Boston, Massachusetts 2008 Honorary Staff, Beth Israel Deaconess Medical Center
Industry Positions:
1992-96 ProScript, Cambridge, Massachusetts, one of 4 founding scientists of ProScript (previously MyoGenics), and member of the board of Directors and Scientific Advisory Board
1992- Merck Research Laboratories, Rahway, New Jersey: consultant 1992-96 Jouveinal, France: Chairman of The Scientific Advisory Board 1993-2002 Creative Biomolecules, Hopkinton, Massachusetts, and then Curis
Pharmaceuticals: Member of the Board of Directors 1993-2003 Abbott Pharmaceutical Co, Abbott Park, Illinois: member of the Scientific Advisory
Committee 1993- HealthCare Ventures, Cambridge, Massachusetts: member of the Scientific
Advisory Board 1995-98 Human Genome Sciences, Rockville, Maryland: member of the Scientific Advisory
Board 1996-2003 Millennium Pharmaceutical Co, Cambridge, Massachusetts: member of the
Scientific Advisory Committee, then consultant 1996- Ferring Pharmaceuticals, Copenhagen, Denmark: Chairman of the Drug
Discovery Committee 1996-2003 ArQule, Inc, Woburn, Massachusetts: member of the Board of Directors 1998-2000 BioVector, France: member of the Board of Directors 1999- Fournier Pharmaceuticals, France: member of the Scientific Advisory Board 2001-04 Concurrent Pharmaceuticals, Willow Grove, Pennsylvania: member of the Board
of Directors and the Scientific Advisory Board 2002 Novartis, Switzerland: ad hoc member of the Scientific Advisory Board 2002-05 Ferring, Switzerland: member of the Board of Directors 2002- Warburg Pincus, New York: member of the Life Sciences Advisory Board 2003- Radius Pharmaceuticals, one of 4 founding scientists, Member of Board of
Directors and Scientific Advisory Board 2014- VL26, Inc. (Rubius Therapeutics): member of the Board of Directors
Merck Positions:
1984-87 Vice President for Biological Research 1987-89 Vice President for Biological Research and Molecular Biology 1987-92 Board of Directors, Istituto di Richerche di Biologia Molecolare S.p.A. (Institute for
Molecular Biology Research), Italy 1989-92 Senior Vice President for Research 2009- Executive Vice President and Chief Medical Officer
5
Awards and Honors: 1966 James Gutmann Prize for Excellence in the Humanities, Columbia University, New
York, New York 1968 Stanley Friedman Prize for Excellence in Organic Chemistry, Columbia University 1968 Phi Beta Kappa 1973 Henry Asbury Christian Award, Harvard Medical School, Boston, Massachusetts 1973 Soma Weiss Award of the Harvard Medical Society for the best research paper
presented to the Undergraduate Assembly 1986 Vincent du Vigneaud Award, presented at the Gordon Conference on Chemistry
and Biology of Peptides, awarded every two years to a scientist(s) age 40 or under: "In recognition of outstanding contributions to the chemistry and biology of peptides and proteins, especially for delineation of the functional domains of parathyroid hormone, synthesis of its leader segment, and labeling of its tissue receptors."
1986 Fuller Albright Young Investigator Award, American Society for Bone and Mineral Research, awarded to a scientist under age 41 "...for outstanding scientific achievement in the field of bone and mineral metabolism."
1988 Citation of Appreciation, Japan Endocrine Society, Sixtieth Annual Fall Meeting, Tokyo, Japan
1989 Chairman's Award, Merck & Company, Inc. 1989 Who's Who In America 1992 Fifth Annual Constantine Anast Lecturer, Children's Hospital and Harvard Medical
School, Boston, Massachusetts 1992 Keynote Speaker, Soma Weiss Undergraduate Research Assembly, Harvard
Medical School: “Career Choice in Biomedical Research: Old Pathways vs. New Pathways, or How Long Can You Keep Your Options Open?”
1993 Musser Lecturer, Tulane University School of Medicine, and elected to Musser-Burch Society
1993 Who's Who in the World 1993 Wohl Lecturer, Temple University School of Medicine, Philadelphia, Pennsylvania 1993 Fellow, American Association for the Advancement of Science 1993 Elected to the Association of Osteobiology 2005 Elected Fellow, American College of Physicians 2006 Best Doctors in America 2010 Honoree “Evening of Hope,” Biomedical Sciences Career Program, Boston,
Massachusetts 2013 Top Chief Medical Officer for 2012, ExecRank
Major Committee Assignments:
National and Regional: 1982-84 Physiological Chemistry Study Section, National Institutes of Health 1982-84 Co-Chairman, 1984 Gordon Conference on Chemistry and Biology of Peptides 1985- Organizing Committee, First Symposium (1987) on New Actions of Parathyroid
Hormone, Kobe, Japan 1988-91 Council Member, American Society for Bone and Mineral Research 1989 Ad Hoc Committee on Issues Facing the United States in Training of Clinical
Investigators, National Academy of Sciences, Institute of Medicine 1990 Panel Member, National Institutes of Health Consensus Development Conference
on Diagnosis and Management of Asymptomatic Primary Hyperparathyroidism
6
1992-95 Board of Scientific Counselors, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health
1996 Special Advisory Committee to Institute Director (Dr. S. Katz), National Institute of Arthritis and Musculoskeletal Diseases, NIH
1997 Hearing of the Subcommittee on Public Health and Safety of the U.S. Senate Labor and Human Resources Committee, “Biomedical Research Priorities: Who Should Decide,” Washington, DC
1998 National Osteoporosis Foundation, Board of Trustees, Scientific Advisory Board 1999 National Institutes of Health Consensus Conference on “Osteoporosis Prevention, Diagnosis, and Therapy,” member of the Planning Committee 2004- Delegate-at-large, Massachusetts Medical Society House of Delegates 2005- Steering Committee, “Gender, Culture and Advancement in Academic Medicine”
C-Change Project 2006- Member, Scientific Advisory Board, Hebrew Rehabilitation Center, Boston,
Massachusetts 2007- Research Innovation and Commercialization Task Force of the Massachusetts Life
Sciences Collaborative 2007 Session Chairperson: Cancer and Bone I, American Society for Bone and Mineral
Research Annual Meeting, Honolulu, Hawaii 2008 Chairman, Special Emphasis Panel, Review of a Program Project Grant
Application, NIDDK, NIH 2008 Scientific Reviewer, Breast Cancer Research Program, U.S. Dept. of Defense 2010- Member, Massachusetts General Hospital Research Advisory Council 2010- Board of Fellows, Harvard Medical School 2010- Member, Institute of Medicine (IOM) Forum on Drug Discovery, Development, and
Translations 2011-14 Member, M.I.T. Corporation Visiting Committee for Whitaker College/Health
Sciences and Technology 2011- Member, Leadership Council University of Pennsylvania, Institute for Diabetes,
Obesity and Metabolism (IDOM) 2013- Member, Massachusetts Biotechnology Council (MassBio) Advisory Board 2013- Council Member, The Pharmaceutical Research and Manufacturers of America
(PhRMA), Scientific Leadership Advisory Council (SLAC) 2013 Member, Institute for Applied Cancer Science (IACS) at M.D. Anderson Cancer
Center Advisory Board 2014- Member, Institute of Medicine (IOM) Roundtable on Value & Science-Driven Health
Care 2014- Member, Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation Board of Directors 2014- Member, Brigham & Women’s Scientific Advisory Board 2014- National Health Council (NHC), Washington, DC
- Member, Board of Directors (2014- ) - Secretary, National Health Council (2016 - ) - Member, Executive Committee (2016 - ) - Ex-Officio Member, Membership Committee (2016 - )
2015- Member, Food and Drug Administration, Office of the Chief Scientist, Office of the Commissioner, Centers of Excellence in Regulatory Science and Innovation (CERSI) Program Evaluation Subcommittee of the Science Board to the Food and Drug Administration
Hospital:
7
1978-79 Executive Secretary, Medical Services Planning Committee for the Ambulatory Care Center, Massachusetts General Hospital, Boston, Massachusetts
1979-84 Subcommittee on Research Materials Management, Committee on Research, Massachusetts General Hospital
1981-84 Intern Selection Committee (Medicine) 1982-84 Chairperson, Committee on Medical Subspecialty Ambulatory Care Practices 1982-84 Chairperson, Program Directors of Endocrinology and Metabolism Training
Program 1992- Appointments and Promotions Board, Department of Medicine, Beth Israel
Hospital, Boston, Massachusetts 1994- Steering Committee, Clinical Investigator Training Program, Harvard-MIT Division
of Health Sciences and Technology, MIT and Beth Israel Hospital Clinical Research Centers
1995-97 Clinical Chairpersons Committee, Beth Israel Hospital 1995-98 President's "Kitchen Cabinet,” Beth Israel Hospital 1996-99 Chairperson, Academic Council, Harvard-Beth Israel Deaconess Mount Auburn
Institute for Education and Research 1996-99 Member, CareGroup Board of Directors 1998-2001 Senior Management Group, CareGroup 1999-2001 Member, Beth Israel Deaconess Medical Center Board of Trustees 2003- Member, Board of Directors (ex officio), Tufts New England Medical Center Medical School: 1972- Aesculapian Club, Harvard Medical School, Boston, Massachusetts 1983-84 Standing Committee, Harvard Medical Society, Boston, Massachusetts 1990 Dean's Committee on Conflict of Interest Guidelines, University of Pennsylvania
School of Medicine, Philadelphia, Pennsylvania 1992-98 Council of Masters, Harvard Medical School Societies, Boston, Massachusetts 1992-2000 Funds for Discovery Program Committee, Harvard Medical School 1992-94 M.D.-Ph.D. Admissions and Program Committee, Harvard Medical School 1992-95 Faculty Council, Harvard Medical School 1993-95 Standing Committee on Conflict of Interest, Harvard Medical School 1994-95 Chairperson, Committee on Governance and Structure of Harvard Medical School 1994-98 M.D.-Ph.D. Program Steering Committee, Harvard Medical School 1996 Member, Harvard University President’s Search Committee for the position of
Dean, Harvard Medical School 2007- Elected Councilor-at-Large, Harvard Medical Alumni Council, Harvard Medical
School
Memberships, Offices, and Committee Assignments in Professional Societies:
1977- American Federation for Clinical Research 1977- American Association for the Advancement of Science 1978- The Endocrine Society 1978- American Society for Bone and Mineral Research 1980-81 Program Committee, Annual Meeting (1981), American Society for Bone and
Mineral Research 1980-81 Program Committee, Seventh American Peptide Symposium (1981) 1980- American Society of Biological Chemists 1981-82 Program Committee, Eighth American Peptide Symposium (1983) 1981-87 Planning Committee, American Peptide Symposia
8
1984- Elected to Membership, American Society for Clinical Investigation 1987 Elected to membership, Association of American Physicians 1988 Chairperson, Workshop on the Hypercalcemia-Associated Peptide of Malignancy:
Structure-Function, Biology, and Genetics, American Society for Bone and Mineral Research
1988-89 Program Committee, American Peptide Symposium 1988-91 Membership Committee for The Endocrine Society 1988 Program Committee, American Society for Bone and Mineral Research 1989- American Association for Cancer Research (membership as “distinguished
investigator,” invited by the President of the Association) 1990-91 Chairman, Nominating Committee, American Peptide Society 1992-94 The Medical Foundation Board of Directors 1992- Interurban Clinical Club 1993- Fellow, American Association for the Advancement of Science 1995- Charter Member, Association of Osteobiology 1996- Chairperson, Workshop on “The Future of Clinical Investigation,” American Society
for Bone and Mineral Research 1997-98 President, Interurban Clinical Club 1997-98 President, American Society for Bone and Mineral Research (the largest
professional society in this field in the world; it has over 3,000 members and approximately 5,00 attendees at its annual meeting)
2003-06 Annual Meeting Steering Committee, The Endocrine Society 2006- Commercial Club and Merchants Club of Boston 2008- Medical Exchange Club, Boston 2009- American Clinical and Climatological Association 2009 - Member, Advisory Board, USA-India Chamber of Commerce 2010 - Honorary member Board of Trustees, Longwood Symphony Orchestra 2011 - Member, Board of Directors, Biomedical Sciences Career Program (BCSP),
Harvard Medical School 2011 - Member, Advisory Council, Association of Academic Health Centers (AAHC)
Washington, DC 2015 - Chair, BioMedical Advisory Council (BMAC), Pharmaceutical Research and
Manufacturers of America (PhRMA) 2015 Program Co-Chair, Drug Information Association (DIA) 2015 51st Annual Meeting
Editorial Boards:
1986-90 Bone and Mineral Research 1989-93 Endocrinology 1990-93 Journal of Bone and Mineral Research 1994-98 Bone
Extra-curricular Community Service
2015 - Overseer, Boston Symphony Orchestra (BSO), Boston, MA 2015 - Project HOPE, member of the Board of Directors
Patents:
12/27/83 Inhibitors of peptide hormone action-4,423,037 05/23/88 Parathyroid hormone antagonists-0293158A2
9
09/13/88 Parathyroid hormone antagonists with simplified synthetic methodology-4,771,124 05/08/89 Humoral hypercalcemic factor antagonists-0341962A2 05/08/89 Parathyroid hormone antagonists-0341963A2 04/19/90 Peptide derivatives-0478775A1 11/06/90 Parathyroid hormone antagonists-4,968,669 03/19/91 Parathyroid hormone antagonists with enhanced metabolic properties-5,001,223 04/12/91 Parathyroid hormone antagonists-0451867A1 09/25/91 Parathyroid hormone derivatives-0477885A2 02/11/92 Humoral hypercalcemic factor antagonists modified at Position 13 by Biotin-
5,087,561 02/11/92 Humoral hypercalcemic factor antagonists modified at Position 13...-5,087,562 03/03/92 PTH Antagonists with Position 13 modification-5,093,233 05/08/92 Inhibiting osteoclast-mediated bone resorption using aminoalkyl-substituted phenyl
derivatives-0528586A1 05/08/92 Inhibiting osteoclast-mediated bone resorption using substituted phenyl
derivatives-0528587A1 05/19/92 Humoral hypercalcemic factor antagonists-5,114,843 03/18/93 Parathyroid hormone derivatives-0561412A1 02/10/98 Cyclic Analogs of PTH and PTHrP-5,717,062 05/05/98 Continuous low-dose administration of parathyroid hormone or its agonist-
5,747,456
Major Research Interests: 1. Parathyroid hormone: design, synthesis, and biological evaluation of analogues, especially
hormone antagonists 2. Parathyroid hormone-related protein: biology and molecular biology of the tumor-secreted
protein responsible for humoral hypercalcemia of malignancy 3. Structural biology of PTH—PTH receptor interactions: complexes, photoaffinity labeling,
isolation, and characterization of hormone-receptor; mapping of hormone-receptor "contact points"
4. Osteoporosis and bone biology: osteoclast integrins and bone resorption 5. Mechanisms of cancer (particularly breast) “homing” to bone Major Administrative Responsibilities:
1981-84 Chief, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 1984-87 Vice President for Biological Research, Merck & Co., Inc., West Point,
Pennsylvania 1987-89 Vice President for Biological Research and Molecular Biology, Merck & Co., Inc. 1989-92 Senior Vice President for Research, Merck & Co., Inc. 1992-98 Director, Harvard-MIT Division of Health Sciences and Technology, Boston and
Cambridge, Massachusetts 1992-2000 Chief, Division of Bone and Mineral Metabolism, Beth Israel Hospital 1996-2000 Executive Director, Carl J. Shapiro Institute for Education and Research at Harvard
Medical School and Beth Israel Deaconess Mount Auburn Institute for Education and Research
10
1996-2000 Senior Vice President for Academic Affairs, Beth Israel Deaconess Medical Center and CareGroup
1996-2000 Harvard Faculty Dean for Academic Programs at Beth Israel Deaconess Medical Center and CareGroup
1999-2001 President, Beth Israel Deaconess Medical Center 2003-2009 Dean, Tufts University School of Medicine
Lectures and Teaching Experience:
1976-84 Conference Leader, Bone and Mineral Metabolism Course for second year
students, Harvard Medical School, Boston, Massachusetts 1976 Endocrine Grand Rounds, Massachusetts General Hospital, Boston,
Massachusetts, “Design of Peptide Hormone Analogues” 1976-78 Instructor, “Introduction to Clinical Medicine,” Harvard Medical School, 1977-84 Lecturer, Medical Housestaff, Massachusetts General Hospital, “Clinical Issues in
Hyperparathyroidism” and “Endorphins and Enkephalins” 1977 Endocrine Grand Rounds, Massachusetts General Hospital, “Parathyroid
Hormone-Receptor Interactions” 1977-78 Attending Physician (Baker Visit), Medical Service, Massachusetts General
Hospital 1978-84 Ambulatory Care Visit, Medical Service, Massachusetts General Hospital 1978-84 Lecturer and Seminar Instructor, Postgraduate Course in Endocrinology,
Department of Continuing Education, Harvard Medical School 1978-84 Outpatient Endocrinology Instructor for Clinical Fellows in Endocrinology,
Massachusetts General Hospital 1978-84 Developer and Organizer, Research Seminars in Basic Endocrinology for Clinical
Fellows in Endocrinology 1979-84 Attending Physician (Bigelow Visit), Medical Service, Massachusetts General
Hospital 1979-84 Endocrine Visit, Medical Service, Massachusetts General Hospital 1979 Lecturer, Postgraduate Course in Oncology, Department of Continuing Education,
Harvard Medical School 1981 Medical Grand Rounds, Massachusetts General Hospital, “The Endogenous
Opiates: Enkephalins and Endorphins” 1982 Lecturer, Postgraduate Course in Medicine, Department of Continuing Education,
Harvard Medical School 1982 Medical Grand Rounds, Massachusetts General Hospital, “Neuropeptides: Medical
Implications for the Future” 1985 Medical Grand Rounds, Massachusetts General Hospital, “Atrial Natriuretic Factor:
A Hormone from the Heart” 1986 Attending Physician, Endocrine Clinic, Hospital of the University of Pennsylvania,
Philadelphia, Pennsylvania 1988-91 Founder and Director, Summer Research Program for Harvard Medical Students,
Merck & Co., Inc. 1989 Endocrine Rounds, University of Pennsylvania School of Medicine, Philadelphia,
Pennsylvania 1989-90 Lecture, Musculoskeletal Course, Harvard Medical School 1989 Lecture, Advanced Pharmacology Course, Columbia College of Physicians and
Surgeons 1989 Visiting Professor, University of Illinois School of Medicine, Chicago, Illinois 1989 Visiting Professor, University of Connecticut Health Center, Farmington,
Connecticut
11
1989 Visiting Professor, Hebrew University - Hadassah Medical Center, Jerusalem, Israel
1989 Visiting Professor, University of California, San Francisco, California 1990 Lecturer, Musculoskeletal Course, Harvard Medical School 1990 Visiting Professor, Washington University School of Medicine, St. Louis, Missouri 1991 Medical Grand Rounds, Beth Israel Hospital, Boston, Massachusetts 1991 Endocrine Grand Rounds, Cedars-Sinai Medical Center, Los Angeles, California 1992 Lecturer, Hypercalcemia Course, Harvard Medical School 1992 Lecturer, Bone Cell Biology Course, Harvard Medical School 1992 Lecturer, Musculoskeletal System Pathophysiology Course, Harvard Medical
School 1992 Lecturer, Capri Workshop on Peptides, “Peptides as Therapeutics: Now and in the
Future” 1992 Plenary Talk, National Center for Research Resources, National Institutes of
Health, “Pharmaceutical R&D and Academia” 1992 Obstetrics and Gynecology Grand Rounds, Beth Israel Hospital, “Controversies in
Management of Menopause” 1992 Attending Physician, Medical Service, Beth Israel Hospital 1993 Medical Grand Rounds, Beth Israel Hospital, “Osteoporosis: Current Concepts and
Future Therapies” 1993 Plenary Talk, American Society for Bone and Mineral Research Annual Meeting,
“Novel Approaches to Inhibition of Bone Resorption” 1993 Musser-Burch Society Lectureship, Tulane University School of Medicine, New
Orleans, Louisiana 1994 Invited Speaker, Harvard-MIT Biotechnology Symposium 1994 Invited Speaker, International Conference on New Actions of Parathyroid
Hormone, Kyoto, Japan 1994 Invited Speaker, Fourth Naples Workshop on Bioactive Peptides, Capri, Italy 1994 Keynote Speaker, European Calcified Tissue Conference, Jerusalem, Israel 1994 Special Address, University of Padua, Italy 1994 Wohl Lecturer, Temple University, Philadelphia, Pennsylvania, “Osteoporosis:
Current Concepts and Future Therapies” 1994 Lecturer, National Osteoporosis Foundation; Continuing Medical Education on
Osteoporosis, Tufts University School of Medicine, Boston, Massachusetts, “New Therapeutic Initiatives in Osteoporosis”
1995 Invited Speaker, Leadership Alliance Symposium, National Academy of Sciences, Washington, D.C.
1995 Medical Grand Rounds, Boston University Medical Center/The University Hospital, Boston, Massachusetts
1995 Medical Grand Rounds, Mt. Auburn Hospital, Cambridge, Massachusetts 1995 St. Louis Endocrine Club, St. Louis, Missouri 1995 Keynote Speaker, NIH Northeast Regional Seminar, Boston, Massachusetts 1995 Visiting Professor, Universidad Nacional de Cuyo, Mendoza, Argentina 1996 Lecturer, Clinical Science Lecture Series, Lawrence and Memorial Hospital, New
London, Connecticut 1996 Lecturer, Department of Obstetrics and Gynecology, Rubin Memorial Grand
Rounds, Beth Israel Hospital, “The New Bisphosphanates” 1996 Invited Speaker, American Association of Clinical Endocrinologists, “Osteoporosis:
An Aggressive Approach for Prevention and Management,” Mount Sinai School of Medicine, New York, New York
1996 Lecturer, Endocrine Grand Rounds, Massachusetts General Hospital
12
1996 Lecturer, Primary Care Internal Medicine: Principles and Practice, Cambridge Center Marriott, Cambridge, Massachusetts
1996 Consultant in Clinical Education, Universidal Nacional de Cuyo, Mendoza, Argentina
1997 Lecturer, Program of the Forum for Medical Education Administrators, Japan, “Challenges and Opportunities in Clinical Education.”
1997 Lecturer, Banyu Seiyaku, “Osteoporosis: Current Concepts and Future Therapies.” 1998 Lecturer, Taiwan, “Alendronate for Osteoporosis: Biology and Therapy.” 1999 Lecturer, Bayer Corporation, Connecticut, “Parathyroid Hormone, Integrins and
other Osteoporosis ‘Targets’.” 1999 Lecturer, Yale University School of Medicine, New Haven, Connecticut
“Parathyroid Hormone and its Interactions with Receptor: an Experimentally-Derived Model.”
2000 Visiting Professor, Mayo Clinic, Rochester, Minnesota 2001 Visiting Professor, Hebrew Rehabilitation Center for Aged, Boston, Massachusetts 2002 Invited speaker, ASBMR-NIH Conference on Osteoporosis Trials: Ethical
Considerations in Study Design, “Industry Viewpoints/Perspectives” 2003 Invited speaker, Genomics Institute of the Novartis Research Foundation,
“Parathyroid hormone, parathyroid hormone-related protein, and bone metastasis,” La Jolla, California
2003 Invited Speaker, Novartis, Basel, Switzerland, “A Novel All-Human Mouse Model of Breast and Prostate Cancer Metastasis to Bone.”
2003 Panel Member, Massachusetts Biotechnology Council, Cambridge, Massachusetts, “From Bench to Bedside.”
2003 Invited Speaker, NASA Marshall Space Center, Huntsville, Alabama, “Fundamentals of Bone Biology and Molecular Mechanisms of Bone Loss.”
2003 Invited Speaker, Breast Cancer Program Project Retreat, Colrain, Massachusetts, “An all-human animal model of breast cancer metastasis to bone.”
2003 Invited Speaker, Cell Signaling Technology, Beverly, Massachusetts, “An all-human animal model of breast cancer metastasis to bone.”
2003 Seminar Speaker, Department of Physiology, Tufts University School of Medicine, “Bones and hormones: parathyroid hormone--receptor interactions and mechanisms of cancer metastasis to bone.”
2005 Keynote Speaker, Robert R. Andrews Honor Society and George A. Bates Research Society Annual Research Dinner, Tufts University School of Dental Medicine
2005 Keynote Speaker, Hambrecht & Quist Biotechnology Conference, “The Academia--Industry Interface: Challenges and Issues” Boston, Massachusetts
2005 Invited Speaker, “Advances in Molecular and Cellular Pathology” Seminar Series, Department of Pathology, Genomics, and Pathobiology, University of Alabama at Birmingham, “Bones, hormones, and cancer: hormone-receptor interactions for parathyroid hormone and development of an animal model of skeletal metastasis.”
2005 Invited Speaker, Whitehead Institute, MIT, Cambridge, Massachusetts, “Development of an animal model of human breast cancer metastasizing to human bone.”
2006 Dean’s Distinguished Lecturer, University of Arkansas Medical School 2006 Invited Speaker, International Regenerative Medicine Foundation Conference,
Kauai, Hawaii, “Regenerating Bone with Parathyroid Hormone.” 2006 Invited Speaker, “Molecular Approaches to Drug Discover,” Working Group on the
Molecular Biology and Pathology of Bone, ASBMR 28th Annual Meeting, Philadelphia, Pennsylvania
13
2006 Invited Speaker, “Development of an “All Human” Animal Model of Breast Cancer Skeletal Metastasis: Studies of Osteotropism,” Genzyme Corporation, Cambridge, Massachusetts
2006 Keynote Speaker, “Medical School Education: Preparing the Foundation for Clinical Practice,” American College of Physicians Massachusetts Chapter Annual Scientific Meeting, Waltham, Massachusetts
2007 Invited Speaker, “Osteotropism: mechanisms of breast cancer to bone,” Regenerative Medicine Organization Annual Meeting, Las Vegas, Nevada
2007 Keynote Speaker, Bone Disease Program Annual Scientific Retreat, University of Texas MD Anderson Cancer Center, Houston, Texas
2008 Invited Speaker, “Bone and Regenerative Medicine,” Regenerative Medicine Organization Annual Meeting, Las Vegas, Nevada
2008 Invited Speaker, “Medical Schools and the Impending Physician Shortage”, Healthcare Financial Management Association, Massachusetts Chapter
2008 Speaker & Panelist, The Endocrine Society’s “Corporate Liaison Board Program on Careers in Industry”, San Francisco, California
2009 Invited Speaker, “Early events in activation of the Parathyroid Hormone Receptor” 14th Annual Maine State Symposium on Osteoporosis 2009 Invited Speaker, "The breast cancer--bone interaction: mechanisms of
metastasis,” University of Massachusetts Medical School, Worcester, Massachusetts
2009 Invited Panelist, “Healthcare, Clinical Research, and Industry-Academic Partnerships,” USA-India BioPharma & Healthcare Summit 2009, Cambridge, Massachusetts
2009 Invited Speaker, Conflict of Interest in Academic Medicine Symposium, Tufts University School of medicine, Boston, Massachusetts
2009 Invited Speaker, Symposium on Advances in G protein-coupled receptor signaling, Endocrine Society Annual Meeting, Washington D.C., “Early events in expression of parathyroid hormone bioactivities”
2009 Invited Panelist, “Innovations in Medical Education,” AMA Section on Medical Schools Meeting, Boston, Massachusetts
2009 Invited Panelist, National Initiatives on Gender, Culture, and Leadership in Medicine: C-Change, “Culture Change in Medical School: From Data to Action” AAMC Annual Meeting, Boston, Massachusetts
2010 54th Rollin T. Woodyatt Lecture, “The Breast Cancer – Bone Interaction: Mechanisms of Metastasis,” Northwestern University Grand Rounds, Chicago, Illinois
2010 Invited Panelist, “Healthcare, Clinical Research, and Industry-Academic Partnerships,” USA-India BioPharma & Healthcare Summit 2010, Cambridge, Massachusetts
2010 Keynote Speaker, “Adjusting for success: the impact of the evolving post-approval landscape,” Post-Approval Summit 2010, Harvard Medical School, Boston, Massachusetts
2010 Invited Panelist, “The Future of Large Biotech and Large Pharma,” World Health Forum, Boston, Massachusetts
2010 Invited Panelist, “Collaborative Models for Improving Global Health,” Georgia Life Sciences Summit 2010, Atlanta, GA
2010 Invited Panelist, “At the interface of academic societies, continuing medical education, and industry,” Annual Meeting, Association of American Medical Colleges, Washington, DC
2010 Invited Panelist “Current Challenges and Future Scenarios for the Pharmaceutical Industry,” Leadership Forum V: Oral Care 2025, Boston, Massachusetts
14
2011 Invited Panelist, “Industry Perspective,” Harvard School of Public Health/Merck Brainstorm Meeting: Improving the Current Data Monitoring Scheme for Clinical Studies in Drug Development, Boston, Massachusetts
2011 Invited Speaker, FASEB Translational Research Meeting, Federation of American Societies for Experimental Biology, Bethesda, MD
2011 Invited Panelist, “Regulation and Governance of Health Research: Perspectives from the United States,” Institute of Medicine, Forum on Drug Discovery, Development, and Translation, Washington DC
2011 Invited Panelist, “Future Directions in Medicine, from the Pharmaceutical Perspective,” Polaris Life Sciences Advisory Board, Jupiter, FL
2011 Invited Panelist, "U.S. Perspectives on UK Academy of Medical Sciences Study: A New Pathway for the Regulation and Governance of Health Research," Institute of Medicine, Forum on Drug Discovery, Development, and Translation, Washington DC
2011 Invited Panelist, “Creating Principled Relationships: Academic Medicine, Research and Industry,” Association of Academic Medical Colleges, Council of Deans Annual Meeting, Chicago, Illinois
2011 Invited Panelist, “Patient Perspectives,” Boston Biotech Business Development Conference, Boston, Massachusetts
2011 Constantine Anast Lecturer, “Translational Research in Academia and Industry: Issues and Opportunities for Working Together,” Children's Hospital and Harvard Medical School, Boston, Massachusetts
2011 Invited Panelist, “3rd Gideon Rodan Memorial Lecture,” 4th New York Skeletal Biology Conference, New York, New York
2011 Invited Panelist, “Strategic Perspectives on Discovery and Development,” MPM Capital Annual Healthcare Leaders Summit, Key Biscayne, Florida
2011 Invited Panelist, “Would changes in the way that the US research enterprise is managed at the highest policy levels improve its effectiveness?” PCAST Planning Meeting -Future of the U.S. Research Enterprise, U.S. President's Council of Advisors on Science and Technology, Washington, D.C.
2011 Invited Panelist, “Pharmaceutical Companies' Perspectives in Post-Market Medical Product Surveillance,” Brookings Active Surveillance Implementation Council, Engelberg Center for Health Care Reform, The Brookings Institution, Washington, D.C.
2011 Invited Speaker, “Careers in Industry,” Endocrine Society Trainee Day Workshop, The Endocrine Society, Boston, MA
2011 Invited Speaker, “Discovering a Drug: The Big Picture,” Intensive Training in Translational Medicine, Harvard Catalyst, Boston, MA
2011 Invited Panelist, “Conversations on Leadership Transitions,” Best Practices in the Evolving Academic Health Center, Association of Academic Health Centers (AAHC), Chicago, IL
2011 Invited Panelist, “The Academe-Industry Interface,” Best Practices in the Evolving Academic Health Center, Association of Academic Health Centers (AAHC), Chicago, IL
2011 Invited Panelist, “The State of Cardiovascular Drug Development,” Cleveland Clinic 2011 Medical Innovation Summit, State of the Heart, Cleveland, OH
2011 Invited Panelist, “Investing in Innovation,” Bicentennial Reunion, Massachusetts General Hospital, Department of Medicine, Boston, MA
2011 Invited Speaker, “A Tale of Mice and (Wo)men: Development of and Insights from an 'All Human' Animal Model of Breast Cancer Metastasis to Bone,” American Clinical and Climatological Association (ACCA), Sarasota, FL
15
2011 Keynote Speaker, “The Barriers to Life Science Innovation: Don't Think Biotech is Immune,” Biotech 2011, Philadelphia, PA
2011 Invited Speaker, “How Can We Save Three Million Mothers?” TEDMED 2011, San Diego, CA
2011 14th Annual John G. Haddad, Jr., MD Memorial Lecturer, “Of mice and (wo)men: studies of breast cancer metastasis to bone and 2) the academia/industry research interface: issues and opportunities,” Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
2011 Invited Panelist, “Incentivizing and Rewarding Innovation,” Financial Times FT Global Pharmaceutical and Biotechnology Conference, London, UK
2011 Invited Speaker, “The Pharmaceutical Industry: Current Challenges and Future Trends,” American Cancer Society, CEO's Against Cancer, University of Medicine and Dentistry, Newark, NJ
2012 Invited Panelist, “Glycoscience: Drug Discovery and Vaccine Development,” National Academy of Sciences, Glycosciences Workshop, Washington, DC
2012 “Of mice and (wo)men: studies of breast cancer metastasis to bone and the academia/industry research interface: issues and opportunities,” University of Maryland School of Medicine, Grand Rounds, Baltimore, MD
2012 Invited Panelist, “Innovation in Academia and Industry - New Models for Collaboration,” Dean's Strategic Planning Leadership Retreat, Stanford University School of Medicine, Santa Cruz, CA
2012 Keynote Speaker, “How Academia and Industry Can Work Together,” Annual Conflicts of Interest Symposium, Tufts University School of Medicine, Boston, MA
2012 Session Chair, “The Role of Academic Health and Science Systems in Creating Responsible Use of Observational Data at the Local and National Level,” Clinical Research Forum, Washington, DC
2012 Invited Panelist, “Novel Relationships between Academic Health and Science Systems and the “Outside World,” Clinical Research Forum, Washington, DC
2012 Invited Speaker “New Directions in Pharmaceutical Innovation,” Annual CEO Leadership Conference, Flagship Ventures, Chatham, MA
2012 Keynote Speaker, “Impact of Real-World and Evidence-Based Medicine for Demonstrating the Safety and Effectiveness of New Therapeutics,” Post-Approval Summit 2012, Harvard Medical School, Boston, Massachusetts
2012 Keynote Speaker, “Collaboration for innovation,” Latin America Journalists Conference, Institute of the Americas, New York Presbyterian Hospital /Columbia University, New York, NY
2012 President's Lecture, “How academia and industry can work together,” American Thoracic Society, San Francisco, CA
2012 Invited Panelist, “The search for innovation from the standpoint of a global firm,” Madrid–MIT M+Visión Consortium, Biomedical Innovation Conference, Madrid, Spain
2012 Invited Speaker, “Creating a Drug: the Big Picture,” Intensive Training in Translational Medicine, Harvard Catalyst, Boston, MA
2012 Keynote Speaker, “How Do We Bring the Best of Medicine to All People?” Sino-American Pharmaceutical Professionals Association – New England (SAPA-NE), Boston, MA
2012 Plenary Speaker, “Discovering a Drug: The Big Picture,” Endo Annual Meeting 2012, The Endocrine Society, Houston, TX
2012 Lecturer, “Academia and Industry: How can we work together,” Dartmouth University, Grand Rounds, Hanover, New Hampshire
2012 Invited Panelist, “Innovations from a Corporate Perspective,” Institute of Medicine, Health Literacy Roundtable, New York, NY
16
2012 Invited Panelist, “Success in Saving Mothers: Interventions and partnerships that drive down maternal deaths worldwide,” Jhpiego, UN General Assembly Week, New York, NY
2012 Panel Moderator, “Alzheimer's Innovation and the White House 2025 Mandate: What Will It Take to Find a Treatment?” Prix Galien Foundation Forum, New York, NY
2012 Keynote Speaker, Bio China, The Biotechnology Industry Organization Convention in China, Shanghai
2012 Keynote Lecture, “Patient Needs, Innovation and Access: Where Will New Medicines Come From?” The 7th Princess Chulabhorn International Science Congress, Bangkok, Thailand
2013 Invited Speaker, Harvard Medical School, Health Policy Course, Boston, MA 2013 Invited Speaker, “Innovation in Biomedicine – the Big Picture,” University of
Connecticut, Farmington, Connecticut 2013 Invited Panelist, “Neurodegenerative Diseases Focusing on Alzheimer’s Disease –
has the time come for a big breakthrough?” Polaris Life Sciences Advisory Board, Jupiter, FL
2013 Invited Speaker, “Regulatory Science: Perspectives,” 2nd Annual Kantoff-Sang Lecture, Harvard Catalyst, Boston, MA
2013 Keynote Lecture, “Inventing drugs for osteoporosis: alendronate and odanacatib (then and now),” MD Anderson & Baylor Scientific Retreat, “The Bone Disease Program of Texas,” Houston, TX
2013 Keynote Lecture, “Big data”: the impact of real-world data on demonstrating the safety and effectiveness of new therapeutics,” MPM Capital Healthcare Leaders Summit & Retreat, Key Biscayne, FL
2013 Invited panelist, “PDUFA V, Biotech Salvation,” MPM Capital Healthcare Leaders Summit & Retreat, Key Biscayne, FL
2013 Keynote Speaker, “Big data”: The Impact on Innovation,” Drug Information Association 2013 Annual Meeting, Boston, MA
2013 Panel Moderator, “Where Research, Medicine and Care Converge: A CMO Roundtable,” Drug Information Association 2013 Annual Meeting, Boston, MA
2013 Invited Panelist, "How can Sweden promote successful clusters in medical research – can we learn from the US?” Almaden, Visby, Sweden
2013 Invited Panelist, “Patient input into benefit/risk issues during drug development and evaluation,” European Medicines Agency, London, UK
2013 Invited Panelist, “The Critical Role of Translational Medicine Capabilities in Academic Health Centers,” Mass General Hospital Clinical Research Day, Boston, MA
2013 Invited Lecturer, “Alendronate & Odanacatib (then and now) and “Treat-to-target (T2T)” National Osteoporosis Symposium, Tokyo, Japan
2013 Panel Chair, “New Mechanisms for Industry-Academia Interactions: Successes and Obstacles” Prix Galien Foundation Forum, New York, NY
2013 Invited Panelist, "Looking Ahead: How Will Innovation Be Influenced by Changing Trends in CER and the Use of Analytics?" New England Health Institute Roundtable, Washington DC
2013 Invited Lecturer, “How Academia and the Pharmaceutical Industry Can Work Together,” Distinguished Lecture Series, Northeastern University, Boston, MA
2013 Invited Panelist, “The Art and Science of Multi-Stakeholder Collaboration,” Partnering for Cures, Faster Cures, New York, NY
2014 Invited Panelist, “Stakeholder Feedback on Mini-Sentinel as a Tool for Evaluating Drug Safety Issues that Require Regulatory Action, Engelberg Center for Health Care Reform, The Brookings Institution, Washington, D.C.
17
2014 Invited Panelist, “Business Case for Healthcare: Lessons from Industry,” Premier Governance Education Conference, Miami Beach, FL
2014 Keynote Speaker, “Outlook for the future of medicine: Where Research, Medicine and Care will Converge,” International Conference on Pharmaceutical Medicine, Berlin, Germany
2014 Invited Panelist, “Data protection in drug development: Patient rights in a changing regulatory landscape,” International Conference on Pharmaceutical Medicine, Berlin, Germany
2014 Invited Panelist, “Sustainable Health Systems – Did we think about the citizen?” EuroMeeting, Drug Information Association, Vienna, Austria
2014 Invited Panelist, “Data: Is It the “.com” for Health Innovation?” National Healthcare Innovation Summit, Boston, MA
2014 Invited Speaker, Harvard Medical School, Health Policy Course, Boston, MA 2014 Invited Panelist, “Clarifying Education & Workforce Training Needs in Regulatory
Science,” PhRMA Foundation, Washington DC 2014 Radio Media Tour Interviewee, Alliance to Reduce Disparities in Diabetes 2014 Invited Panelist, “"Perspectives on Returning Aggregate Results to Study
Participants,” Harvard MRCT Center's 2014 Annual Meeting, Boston, MA 2014 Invited Panelist, “The Importance of Patients,” Boston Biotech Conference, Genetic
Rx, Harvard Medical School, Boston, MA 2014 Invited Panelist, “When All Else Fails: The Promise and Peril of Expanded Access
to Investigational Treatment,” Public Responsibility in Medicine and Research (PRIM&R), Advancing Ethical Research, Baltimore, MD
2015 Invited Speaker, Harvard Medical School, Health Policy Course, Boston, MA 2015 Invited Panelist, "Patient-Focused Drug Development," National Health Council
(NHC) Voluntary Health Leadership, Ponte Vedra, FL 2015 Invited Speaker, Polaris Life Sciences Advisory Board Meeting, Jupiter, FL 2015 Keynote Speaker, “Compassionate Drug Use in Oncology,” Cancer Advance 2015,
Boston, MA 2015 Invited Panelist, “Pharma Medical Affairs: Vision Through 2020,” 27th Annual DIA
Euromeeting, Paris, France 2015 Invited Speaker, Kenneth E. Quickel, Jr., MD Lecture, Joslin Diabetes Center,
Boston, MA 2015 Invited Panelist, “The Future of Clinical Trial Data Sharing,” Drug Information
Association (DIA) 51st Annual Meeting, Washington, DC 2015 Invited Speaker, “The Academia-Industry Interface: Conflict of Interest/Alignment
of Interest,” ITMAT Symposium, UPENN, Philadelphia, PA 2015 Invited Panelist, “Can the CMO make or break the India value proposition?” USA--
India Summit, Cambridge, MA 2015 Invited Speaker, “Regulating Science and Transitional Research: Innovation to
Meet Patient Needs,” University of Rochester, NY 2016 MIT David B. Schauer Lecturer, Cambridge, MA
Grant Support:
Recent Research Grants
NIH Grant No. R01DK47940-01A1, Michael Rosenblatt (Principal Investigator) "Nature of PTH/PTHrP—receptor bimolecular interactions," January 2004 to December
2009. Susan G. Komen Breast Cancer Foundation, Michael Rosenblatt (Principal Investigator)
18
“Elucidating the contribution of bone to breast cancer metastasis using an engineered bone scaffold,” August 2007 to August 2010.
Past Research Grants:
Ferring Research, Ltd., Michael Rosenblatt (Principal Investigator) “Role of fibroblast activation protein (FAP) in human breast cancer metastasis to bone,”
November 2006 to November 2007. Biomeasure Grant, Michael Rosenblatt (Principal Investigator) “Peptides for treatment of metabolic bone disease,” October 1994 to October 1997 Yissum-Hebrew University: grant for a post-doctoral fellow, Michael Rosenblatt (Mentor)
January 1 to December 31, 1995 NIH Clinical Investigator Award, Harold Rosen (Principal Investigator), Michael Rosenblatt (sponsor) “Adjustment of estrogen dosing according to bone turnover,” April 1995 to March 2000 Ariad Pharmaceuticals, Michael Rosenblatt (Principal Investigator) “Development of a novel model of human breast and prostate cancer metastasis to
human bone and assay of therapeutic agents from Ariad,” August 2002 to July 2003. Merck Medical School Grant, Michael Rosenblatt (Principal Investigator) “Evaluation of Fosamax (alendronate) in an animal model of human cancer metastases
to bone,” January 2003 to January 2004. ArQule, Inc., Michael Rosenblatt (Principal Investigator) “Application of human ectopic bone—breast cancer metastasis model,” January 2004 to
December 2004. Ferring Pharmaceuticals, Inc., Michael Rosenblatt (Principal Investigator) “Evaluation of compounds in OVX model,” November 2003 to September 2005. NIH Grant No. R01AR42833-01A1, Michael Rosenblatt (Principal Investigator) "Osteoporosis approach based on bone resorption blockade," July 1999 to June 2005. Cardiovascular Biotherapeutics, Inc., Michael Rosenblatt (Principal Investigator) “Fibroblast growth factor-1 (FGF-1), and the effects of FGF-1 on Bone,” October 2006 to
June 2007. ArQule, Inc., Michael Rosenblatt (Principal Investigator) “Application of human ectopic bone—breast cancer metastasis model,” October 2005 to
September 2007. Amgen, Inc., Michael Rosenblatt (Principal Investigator) “Preclinical Research Agreement/Role of RANK-Ligand in Metastasis,” January 2007 to
August 2008.
Past Educational Grants:
Josiah Macy, Jr. Foundation, Michael Rosenblatt, M.D. (project leader) “The Virtual Patient Project,” July 1997 to June 2000 Merck Company Foundation, Michael Rosenblatt, M.D., "Creation of a Virtual Patient with Osteoporosis," October 1, 1997 to September 30, 1998
Trainees:
Post-Doctoral Fellows: Daniel B. Carr, M.D., Endocrine Fellow, Massachusetts General Hospital (currently Vice Chair
of Research, Tufts-New England Medical Center; CMO, Innovative Drug Delivery Systems)
19
Samuel R. Nussbaum, M.D., Endocrine Fellow, Massachusetts General Hospital (currently Executive Vice President & Chief Medical Officer for WellPoint, Inc.)
Larry Moss, M.D., Endocrine Fellow, Massachusetts General Hospital (currently Chief of Pediatric Surgery and Surgeon-in-Chief, Yale School of Med and Yale Children’s Hospital)
Rachelle Halpern, M.D., Endocrine Fellow, Massachusetts General Hospital (currently a doctor at a medical practice in Berkeley, CA)
Noburo Horiuchi, Massachusetts General Hospital (currently Associate Professor, Ohu University, School of Dentistry, Japan)
Le T. Duong, Merck Research Laboratories (currently Sr. Research Fellow, Dept. of Molecular Endocrinology/Bone Biology at Merck)
Bonny Wright, Merck Research Laboratories Eli Roubini, Merck Research Laboratories Roberta McKee, Merck Research Laboratories (currently Senior Vice President of Worldwide
Quality & Compliance at Bristol-Myers Squibb) Yoav Eshel, Beth Israel Hospital and Harvard Medical School (currently a Sales Manager at
DSL Israel Ltd.) Rivka Dresner-Pollak, Beth Israel Hospital and Harvard Medical School (currently Associate
Professor of Medicine, Hebrew University, Jerusalem, Israel) Miriam Royo Exposito, Beth Israel Hospital and Harvard Medical School (currently holds a
faculty position at the University of Barcelona, Barcelona, Spain) Roberto Betzalel, Beth Israel Hospital and Harvard Medical School (currently holds a faculty
position at the University of Concepcion, Concepcion, Chile) Alice Ti Zhou, Beth Israel Hospital and Harvard Medical School (currently holds a postdoctoral
position at Massachusetts General Hospital, Boston, MA) LiYa Tang, Beth Israel Hospital and Harvard Medical School (current position of Senior
Research Scientist, Dept. of Osteoporosis, Bayer Pharmaceutical Co., West Haven, CT) Kathy Traianedes, Beth Israel Hospital and Harvard Medical School (currently holds a position
as Senior Scientist, Australian Stem Cell Centre, Ltd., Monash University, Australia) Michiko Yamamoto, M.D., Merck Research Laboratories (currently Professor in the Dept. of
Health & Nutrition at Niigata University of Health & Welfare, Niigata, Japan) Chizu Nakamoto, Beth Israel Deaconess Medical Center and Harvard Medical School (currently
holds a position at The Cleveland Clinic Foundation in Cleveland, OH) Alessandro Bisello, Beth Israel Deaconess Medical Center and Harvard Medical School
(currently Assistant Professor of Medicine and Pharmacology, University of Pittsburgh School of Medicine)
Zvi Greenberg, Beth Israel Deaconess Medical Center and Harvard Medical School Gal Bitan, Beth Israel Deaconess Medical Center and Harvard Medical School (currently
Instructor in Neurology, Brigham & Women’s Hospital and Harvard Medical School, Boston)
Norbert Sule, Beth Israel Deaconess Medical Center and Harvard Medical School Qiong Zhao, Beth Israel Deaconess Medical Center and Harvard Medical School (currently a
cardiologist in Chicago, IL) Serge Ferrari, Beth Israel Deaconess Medical Center and Harvard Medical School (currently
Swiss National Science Foundation (SNF) Professor of Medicine in the Division of Bone Diseases, Department of rehabilitation and Geriatrics at the University Hospital in Geneva, Switzerland)
Lukas Scheibler, Beth Israel Deaconess Medical Center and Harvard Medical School (currently a scientist at Roche Pharmaceuticals in Basel, Switzerland)
Yinglin Han, Beth Israel Deaconess Medical Center and Harvard Medical School LiQiang Tou, Beth Israel Deaconess Medical Center and Harvard Medical School (currently a
scientist at Novartis in Cambridge, MA)
20
Dror Yahalom, Beth Israel Deaconess Medical Center and Harvard Medical School Angela Wittelsberger, Beth Israel Deaconess Medical Center and Harvard Medical School and
Tufts University School of Medicine (currently at Research Instructor at Tufts University School of Medicine)
Byung-Kwon Lee, Beth Israel Deaconess Medical Center and Harvard Medical School (currently Research Assistant Professor, Department of Microbiology, University of Tennessee)
Alessandra Barazza, Beth Israel Deaconess Medical Center (currently holds a position at the Max Planck Institute)
Piotr Ruchala, Beth Israel Deaconess Medical Center (currently Postdoctoral Fellow, Dept. of Pathology, Harvard Medical School; Research Fellow, Dept. of Cancer Immunology & AIDS, Dana-Farber Cancer Institute)
Lu Gan, Beth Israel Deaconess Medical Center and Tufts University School of Medicine (currently a researcher at Vertex Pharmaceuticals)
Kristen Anderson, Beth Israel Deaconess Medical Center and Tufts University School of Medicine
Charlotte Kuperwasser, Tufts University School of Medicine Atta Ahmad, Tufts University School of Medicine (currently a post-doc at the University of
California at Santa Cruz) Iwona Woznica, Tufts University School of Medicine Paul Monaghan, Tufts University School of Medicine (currently a scientist at New England
Biolabs) Jodie Moreau, Tufts University School of Medicine (currently a scientist at Wyeth
Pharmaceuticals) Beena Thomas, Tufts University School of Medicine Sijin Liu, Ph.D., Tufts University School of Medicine (currently State Key Lab of Environmental
Chemistry, Chinese Academy of Sciences) Edi Goihberg, Tufts University School of Medicine (currently at Beth Israel Deaconess Medical
Center) Paul Mathew, Tufts University School of Medicine (currently at Tufts Medical Center) Ellen Scepansky, Tufts University School of Medicine (currently in private practice of oncology) MD/PhD Students: Amy Adams, Harvard-MIT Division of Health Sciences and Technology (currently Postdoctoral
Fellow at Stanford University) Robert Goldstein, Tufts University School of Medicine Graduate Students: Michael Gertner, Harvard-MIT Division of Health Sciences and Technology Vered Rashti-Behar, Division of Medical Sciences, Harvard University, (Winner: American
Society for Bone & Mineral Research President’s Award for Best Abstract by a Young Investigator - 1997)
Cheryll Sanchez, Harvard BBS Student Medical Students: Alan Shuldiner, Harvard-MIT Division of Health and Sciences and Technology (currently
Professor and Head, Division of Endocrinology, Diabetes and Nutrition at the University of Maryland School of Medicine and Director of the Joslin Diabetes Center, Baltimore, MD)
21
Marc Coltrera, Yale University School of Medicine Kingsley Chin, Harvard Medical School (currently Resident, Harvard Orthopedic Training
Program) Paul Wang, Harvard-MIT Division of Health Sciences and Technology Matt Halpern, Harvard Medical School Tuan Tran, Tufts University School of Medicine Edward Tangchitnob, Tufts University School of Medicine
Trainee Awards:
1995 Amy Adams, National Osteoporosis Foundation Student Award Grant 1995 Vered Rashti-Behar, National Osteoporosis Foundation Student Award Grant 1996 Vered Rashti-Behar, President's Book Award-American Society for Bone and Mineral
Research, for highest rated student abstract (1,600 abstracts submitted, 4,000 participants)
1999 Alessandro Bisello, Advance in Mineral Metabolism-American Society for Bone and Mineral Research – Young Investigator Award
1998- Serge Ferrari, American Society for Bone Mineral Research – Young Investigator Award
2009 Sijin Liu, American Society for Bone and Mineral Research – Young Investigator Award
Original (Peer-Reviewed) Reports: 1. Quinn RS, Rosenblatt M, Krane SM. Proteolytic activity in human skin fibroblasts harvested
with trypsin and its effect on measurements of collagen hydroxylase activities. Biochem Biophys Res Commun 1976; 71:300-306.
2. Rosenblatt M, Goltzman D, Keutmann HT, Tregear GW, Potts JT Jr. Chemical and biological
properties of synthetic, sulfur-free analogues of parathyroid hormone. J. Biol. Chem. 1976; 251:159-164.
3. Rosenblatt M, Callahan EN, Mahaffey JE, Pont A, Potts JT Jr. Parathyroid hormone
inhibitors: design, synthesis, and biologic evaluation of hormone analogues J. Biol. Chem. 1977; 252:5847-5851.
4. Rosenblatt M, Keutmann HT, Tregear GW, Potts JT Jr. Synthesis of a fragment of human
parathyroid hormone, hPTH-(44--68). J. Med. Chem. 1977; 20:1452-1456. 5. Rosenblatt M, Potts JT Jr. Design and synthesis of parathyroid hormone analogues of
enhanced biological activity. Endocrine Res Commun 1977; 4:115-133. 6. Rosenblatt M, Segre GV, Potts JT Jr. Synthesis of a fragment of parathyroid hormone,
bPTH-(28--48): an inhibitor of hormone cleavage in vivo. Biochemistry 1977; 16:2811-2816. 7. Habener JF, Rosenblatt M, Kemper B, Kronenberg HM, Rich A, Potts JT Jr. Pre-
proparathyroid hormone: amino acid sequence, chemical synthesis, and some biological studies of the precursor region. Proc. Natl. Acad. Sci. USA 1978; 75:2616-2620.
22
8. Rosenblatt M, Segre GV, Tregear GW, Shepard GL, Tyler GA, Potts JT Jr. Human parathyroid hormone: synthesis and chemical, biological, and immunological evaluation of the carboxyl-terminal region. Endocrinology 1978;103:978-984.
9. Rosenblatt M, Shepard GL, Tyler GA, Potts JT Jr. Modification of the arginines in parathyroid
hormone: effect on biological activity. Biochemistry 1978; 17:3188-3191. 10. Goldring SR, Mahaffey JE, Rosenblatt M, Dayer J-M, Potts JT Jr, Krane SM. Parathyroid
hormone inhibitors: comparison of biological activity in bone and skin-derived tissue. J. Clin. Endocrinol. Metab. 1979; 48:655-659.
11. Habener JF, Rosenblatt M, Dee PC, Potts JT Jr. Cellular processing of pre-proparathyroid
hormone involves rapid hydrolysis of the leader sequence. J. Biol. Chem. 1979; 254:10596-10599.
12. Hendy GN, Manning RM, Rosenblatt M, Tregear GW, Keutmann HT, O'Riordan JLH.
Immunological properties of synthetic human parathyroid hormone 53--84 fragment. J. Endocrinol. 1979; 80:153-159.
13. Mahaffey JE, Rosenblatt M, Shepard GL, Potts JT Jr. Parathyroid hormone inhibitors:
determination of minimum sequence requirements. J. Biol. Chem. 1979; 254:6496-6498. 14. Raisz LG, Lorenzo J, Gworek S, Kream B, Rosenblatt M. Comparison of the effects of a
potent synthetic analog of bovine parathyroid hormone with native bPTH-(1--84) and synthetic bPTH-(1--34) on bone resorption and collagen synthesis. Calcif. Tissue Int. 1979; 29:215-218.
15. Rosenblatt M, Habener JF, Tyler GA, Shepard GL, Potts JT Jr. Chemical synthesis of the
precursor-specific region of pre-proparathyroid hormone. J. Biol. Chem. 1979; 254:1414-1421.
16. Segre GV, Rosenblatt M, Reiner BL, Mahaffey JE, Potts JT Jr. Characterization of
parathyroid hormone receptors in canine renal cortical plasma membranes using a radioiodinated sulfur-free hormone analogue: correlation of binding with adenylate cyclase activity. J. Biol. Chem. 1979; 254:6980-6986.
17. Ausiello DA, Rosenblatt M, Dayer J-M. Parathyroid hormone modulates protein kinase in
giant cell tumors of human bone. Am. J. Physiol. 1980; 239:E144-E149. 18. Chen TC, Rosenblatt M, Puschett JB. Effects of calcium on a parathyroid hormone-sensitive
adenylate cyclase inhibitor. Biochem. Biophys. Res. Commun. 1980; 94:1227-1232, 1980. 19. Coltrera M, Rosenblatt M, Potts JT Jr. Analogues of parathyroid hormone containing D-amino
acids: evaluation of biological activity and stability. Biochemistry1980; 19:4380-4385. 20. Majzoub JA, Rosenblatt M, Fennick B, Maunus R, Kronenberg HM, Potts JT Jr, Habener JF.
Synthetic pre-proparathyroid hormone leader sequence inhibits cell-free processing of placental, parathyroid, and pituitary prehormones. J. Biol. Chem. 1980; 255:11478-11483.
21. Nussbaum SR, Rosenblatt M, Potts JT Jr. Parathyroid hormone renal receptor interactions:
demonstration of two receptor-binding domains. J. Biol. Chem. 1980; 255:10183-10187.
23
22. Rosenblatt M, Tregear GW, Shepard GL, Tyler GA, Veroni M, Potts JT Jr. Comparison of two solid-phase peptide syntheses of a 32-amino acid carboxyl-terminal fragment of human parathyroid hormone, hPTH-(53-84). Arch. Biochem. Biophys. 1980; 199:286-296.
23. Rosenblatt M, Beaudette NV, Fasman GD. Conformational studies of the synthetic precursor-
specific region of pre-proparathyroid hormone. Proc. Natl. Acad. Sci USA 1980; 77:3983-3987.
24. Rosenblatt M, Segre GV, Tyler GA, Shepard GL, Nussbaum SR, Potts JT Jr. Identification of
a receptor-binding region in parathyroid hormone. Endocrinology 1980; 107:545-550. 25. Bergeron JJM, Tchervenkov S, Rouleau MF, Rosenblatt M, Goltzman D. In vivo
demonstration of receptors in rat liver to the amino-terminal region of parathyroid hormone. Endocrinology 1981; 109:1552-1559.
26. Carr DB, Bullen BA, Skrinar GS, Arnold MA, Rosenblatt M, Beitins IZ, Martin JB,
McArthur JW. Physical conditioning facilitates the exercise-induced secretion of beta-endorphin and beta-lipotropin in women. N. Engl. J. Med. 1981; 305:560-563.
27. Carr DB, Reppert SM, Bullen B, Skrinar G, Beitins I, Arnold M, Rosenblatt M, Martin JB,
McArthur JW. Plasma melatonin increases during exercise in women. J. Clin. Endocrinol. Metab. 1981; 53:224-225.
28. Coltrera MD, Potts JT Jr, Rosenblatt M. Identification of a renal receptor for parathyroid
hormone by photoaffinity radiolabeling using a synthetic analogue. J. Biol. Chem. 1981; 256:10555-10559.
29. Goldring SR, Dayer J-M, Rosenblatt M. Factors regulating the response of cells cultured from
human giant cell tumors of bone to parathyroid hormone. J. Clin. Endocrinol. Metab. 1981; 53:295-300.
30. Mallette LE, Renfro M, Lemoncelli J, Rosenblatt M. Radioimmunoassays for the 28--48
region of parathyroid hormone detect intact hormone but not hormone fragments. Calcif. Tissue Int. 1981; 33:375-380.
31. Martin KJ, Bellorin-Font E, Freitag J, Rosenblatt M, and Slatopolsky E. The arterio-venous
difference for immunoreactive parathyroid hormone and the production of adenosine 3',5'-cyclic monophosphate by isolated perfused bone: studies with analogs of parathyroid hormone. Endocrinology 1981; 109:956-959.
32. Marx SJ, Sharp ME, Krudy A, Rosenblatt M, Mallette LE. Radioimmunoassay for the middle
region of human parathyroid hormone: studies with a radioiodinated synthetic peptide. J. Clin. Endocrinol. Metab. 1981; 53:76-84.
33. Rosenblatt M, Coltrera MD, Shepard GL, Gray DA, Parsons JA, Potts JT Jr. Sulfur-free
parathyroid hormone analogues containing D-amino acids: biological properties in vitro and in vivo. Biochemistry 1981; 20:7246-7250.
34. Rosenblatt M, Potts JT Jr. Analogues of an in vitro parathyroid hormone inhibitor:
modifications at the amino terminus. Calcif. Tissue Int. 1981; 33:153-157.
24
35. D'Amour P, Huet P-M, Segre GV, Rosenblatt M. Characteristics of bovine parathyroid hormone extraction by the dog liver in vivo. Am. J. Physiol. 1981; 241 (Endocrinol. Metab. 4):E208-E214.
36. Manning RM, Adami S, Papapoulos SE, Gleed JH, Hendy GN, Rosenblatt M, O'Riordan JLH.
A carboxy-terminal specific assay for human parathyroid hormone. Clin. Endocrinol. 1981; 15:439-449.
37. Carr DB, Bergland R, Hamilton A, Blume H, Kasting N, Arnold M, Martin JB, Rosenblatt M.
Endotoxin-stimulated opioid peptide secretion: two secretory pools and feedback control in vivo. Science 1982; 217:845-848.
38. Gray DA, Parsons JA, Potts JT Jr, Rosenblatt M, Stevenson RW. In vivo studies on an
antagonist of parathyroid hormone [Nle-8,Nle-18,Tyr-34]bPTH-(3--34)amide. Br. J. Pharmacol. 1982; 76:259-263.
39. McGowan JA, Chen TC, Fragola J, Puschett JB, Rosenblatt M. Parathyroid hormone: effects
of the 3--34 fragment in vivo and in vitro. Science 1983; 219:67-69. 40. Horiuchi N, Holick MF, Potts JT Jr, Rosenblatt M. A parathyroid hormone inhibitor in vivo:
design and biological evaluation of a hormone analog. Science 1983; 220:1053-1055. 41. Horiuchi N, Rosenblatt M, Keutmann HT, Potts JT Jr, Holick MR. A multiresponse
parathyroid hormone assay: an inhibitor has agonist properties in vivo. Am. J. Physiol. 1983; 244 (Endocrinol. Metab. 7) :E589-595.
42. Lechan RM, Goodman RH, Rosenblatt M, Reichlin S, Habener JF. Prosomatostatin-specific
antigen in rat brain: localization by immuno- cytochemical staining with an antiserum to a synthetic sequence of preprosomatostatin. Proc. Natl. Acad. Sci. 1983; 80:2780-2784.
43. Nussbaum SR, Carr DB, Bergland RM, Kliman B, Fisher J, Reiner B, Kleshinski S,
Rosenblatt M. Dynamics of cortisol and endorphin responses to graded doses of synthetic ovine CRF in sheep. Endocrinology 1983; 112:1877-1879.
44. Rafferty B, Zanelli JM, Rosenblatt M, Schulster D. Corticosteroidogenesis and adenosine
3',5'-monophosphate production by the amino-terminal (1-34) fragment of human parathyroid hormone in rat adrenocortical cells. Endocrinology 1983;113:1036-1042.
45. Tyler GA, Rosenblatt M. Semi-preparative high-performance liquid chromatographic
purification of a 28-amino acid synthetic parathyroid hormone antagonist. J. Chromatogr. 1983; 266:313-318.
46. Goldring SR, Tyler GA, Krane SM, Potts JT Jr, Rosenblatt M. Photoaffinity labeling of
parathyroid hormone receptors: comparison of receptors across species and target tissues and after desensitization to hormone. Biochemistry 1984; 23:498-502.
47. Wright RD, Blair-West JR, Nelson JF, Tregear GW, Rosenblatt M. Evaluation of the
biological properties of parathyroid hormone and analogues in a vascularly isolated parotid gland-based assay. J. Endocrinol. 1984;102:375-379.
25
48. Puschett JB, McGowan J, Fragola J, Chen TC, Keutmann H, Rosenblatt M. Difference between 1--84 parathyroid hormone and the 1--34 fragment on renal tubular calcium transport in the dog. Miner. Electrolyte Metab. 1984; 10:271-274.
49. Shuldiner AR, Newland RJ, Rosenblatt M. N-Cyclo-[Leu5]enkephalin: a rational approach for
the synthesis of conformationally restricted cyclic pentapeptides. Arch. Biochem. Biophys. 1985; 238:111-117.
50. Segre GV, Rosenblatt M, Tully GL III, Laugharn J, Reit B, Potts JT Jr. Evaluation of an in
vitro parathyroid hormone antagonist in vivo in dogs. Endocrinology 1985;116:1024-1029. 51. Takano T, Takigawa M, Shirai E, Suzuki F, Rosenblatt M. Effects of synthetic analogs and
fragments of bovine parathyroid hormone on adenosine 3',5' monophosphate level, ornithine decarboxylase activity, and glycosaminoglycan synthesis in rabbit costal chondrocytes in culture: structure-activity relations. Endocrinology 1985;116:2536-2542.
52. Epand RM, Epand RF, Hui SW, He NB, Rosenblatt M. Formation of water-soluble complex
between the 1--34 fragment of parathyroid hormone and dimyristoylphosphatidylcholine. Int. J. Pept. Protein Res. 1985; 25:594-600.
53. Weinberger SE, Steinbrook RA, Carr DB, Von Gal ER, Fisher JE, Leith DE, Fencl V,
Rosenblatt M. Endogenous opioids and ventilatory responses to hypercapnia in normal humans. J. Appl. Physiol. 1985; 58:1415-1420.
54. Steinbrook RA, Weinberger SE, Carr DB, Von Gal E, Fisher J, Leith DE, Fencl V, Rosenblatt
M. Endogenous opioids and ventilatory responses to hypoxia in normal humans. Am. Rev. Respir. Dis. 1985;131:588-591.
55. Keutmann HT, Griscom AW, Nussbaum SR, Reiner BF, Goud AN, Potts JT Jr, Rosenblatt M.
Rat parathyroid hormone-(1--34) fragment: renal adenylate cyclase activity and receptor binding properties in vitro. Endocrinology 1985; 117:1230-1234.
56. Goldring SR, Roelke MS, Bringhurst FR, Rosenblatt M. Differential effects of parathyroid
hormone responsive cultured human cells on biological activity of parathyroid hormone and parathyroid hormone inhibitory analogues. Biochemistry 1985; 24:513-518.
57. Nussbaum SR, Beaudette NV, Fasman GD, Potts JT Jr, Rosenblatt M. Design of analogues
of parathyroid hormone: a conformational approach. J. Protein Chem. 1985; 4:391-406. 58. Caulfield MP, Duong LT, Rosenblatt M. Demonstration of post-translational secretion of
human placental lactogen by a mammalian in vitro translation system. J. Biol. Chem. 1986; 261:10953-10956.
59. Gleed JH, Hendy GN, Nussbaum SR, Rosenblatt M, O'Riordan JLH. Development and
application of a mid-region specific assay for human parathyroid hormone. Clin. Endocrinol. (Oxf.) 1986; 24:365-373.
60. Doppelt SH, Neer RM, Nussbaum SR, Federico P, Potts JT Jr, Rosenblatt M. Inhibition of the
in vivo parathyroid hormone-mediated calcemic response in rats by a synthetic hormone antagonist. Proc. Natl. Acad. Sci. USA 1986; 83:7557-7560.
26
61. Wright BS, Tyler GA, O'Brien R, Caporale LH, Rosenblatt M. Immunoprecipitation of the parathyroid hormone receptor. Proc. Natl. Acad. Sci. USA 1987; 84:26-30.
62. Weinberger SE, Steinbrook RA, Carr DB, Fencl V, Gabel RA, Leith DR, Fisher JE, Harris R,
Rosenblatt M. Endogenous opioids and ventilatory adaptation to prolonged hypoxia in goats. Life Sci. 1987; 40:605-613.
63. Duong LT, Caulfield MP, Rosenblatt M. Synthetic signal peptide and analogs display different
activities in mammalian and plant in vitro secretion systems. J. Biol. Chem. 1987; 262:6328-6333.
64. Horiuchi N, Rosenblatt M. Evaluation of a parathyroid hormone antagonist in an in vivo
multiparameter bioassay. Am. J. Phys. 1987; 253:E187-E192. 65. Tosteson MT, Levy JJ, Caporale LH, Rosenblatt M, Tosteson DC. Solid-phase synthesis of
melittin: purification and functional characterization. Biochemistry 1987; 26:6627-6631. 66. Strewler GJ, Stern PH, Jacobs JW, Eveloff J, Klein RF, Leung SC, Rosenblatt M, Nissenson
RA. Parathyroid hormone-like protein from human renal carcinoma cells: structural and functional homology with parathyroid hormone. J. Clin. Invest. 1987; 80:1803-1807.
67. Horiuchi N, Caulfield MP, Fisher JE, Goldman ME, McKee RL, Reagan JE, Levy JJ, Nutt RF,
Rodan SB, Schofield TL, Clemens TL, Rosenblatt M. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 1987; 238:1566-1568.
68. Condra CL, Leidy EA, Bunting P, Colton CD, Nutt RF, Rosenblatt M, Jacobs JW. Clearance
and early hydrolysis of atrial natriuretic factor in vivo: structural analysis of cleavage sites and design of an analogue that inhibits hormone cleavage. J. Clin. Invest. 1988; 81:1348-1343.
69. Rodan SB, Noda M, Wesolowski G, Rosenblatt M, Rodan GA. Comparison of postreceptor
effects of 1-34 human hypercalcemia factor and 1-34 human parathyroid hormone in rat osteosarcoma cells. J. Clin. Invest. 1988; 81:924-927.
70. Caulfield MP, Duong LT, O'Brien R, Majzoub JA, Rosenblatt M. A chemically synthesized
radiolabeled signal peptide: design, preparation, and biological evaluation of an iodinated analog of preproparathyroid hormone. Mol. Endocrinol. 1988; 2:452-458.
71. McKee RL, Goldman ME, Caulfield MP, DeHaven PA, Levy JJ, Nutt RF, Rosenblatt M. The
7-34-fragment of human hypercalcemia factor is a partial agonist/antagonist for parathyroid hormone-stimulated cAMP production. Endocrinology 1988; 122:3008-3010.
72. Tosteson MT, Caulfield MP, Levy JJ, Rosenblatt M, Tosteson DC. The synthetic precursor
specific region of pre-pro-parathyroid hormone forms ion channels in lipid bilayers. Biosci. Rep. 1988; 8:173-183.
73. Thiede MA, Strewler GJ, Nissenson RA, Rosenblatt M, Rodan GA. Human renal carcinoma
expresses two messages encoding a parathyroid hormone-like peptide: evidence for the alternative splicing of a single-copy gene. Proc. Natl. Acad. Sci. USA 1988; 85:4605-4609.
74. Thompson DD, Seedor JG, Fisher JE, Rosenblatt M, Rodan GA. Direct action of the
parathyroid hormone-like human hypercalcemic factor on bone. Proc. Natl. Acad. Sci USA 1988; 85:5673-5677.
27
75. Goldman ME, Chorev M, Reagan JE, Nutt RF, Levy JJ, Rosenblatt M. Evaluation of novel
parathyroid hormone analogs using a bovine renal membrane receptor binding assay. Endocrinology 1988; 123:1468-1475.
76. Goldman ME, McKee RL, Caulfield MP, Reagan JE, Levy JJ, Gay CT, DeHaven PA,
Rosenblatt M, Chorev M. A new highly potent parathyroid hormone antagonist: [D-Trp12,Tyr34]bPTH-(7--34)NH2. Endocrinology 1988; 123:2597-2599.
77. Caulfield MP, Levy JJ, McKee RL, Goldman ME, DeHaven PA, Reagan JE, Heaney L, Nutt
RF, Winquist RJ, Russell J, Sherwood LM, Rosenblatt M. Avian (chicken) parathyroid hormone: synthesis and comparative biological evaluation of the 1-34 fragment. Endocrinology 1988; 123:2949-2951.
78. Caporale L, Nutt R, Levy J, Smith J, Arison B, Bennett C, Albers-Schonberg G, Pitzenberger
S, Rosenblatt M, Hirschmann, R. Characterization of synthetic parathyroid hormone analogues and of synthetic byproducts. J. Org. Chem. 1989; 54:343-346.
79. Caulfield MP, Duong LT, Baker RK, Rosenblatt M, Lively MO. Synthetic substrate for
eukaryotic signal peptidase: Cleavage of a synthetic peptide analog of the precursor region of preproparathyroid hormone. J. Biol. Chem. 1989; 264:15813-15817.
80. Chorev M, Goldman ME, McKee RL, Roubini E, Levy JJ, Gay CT, Reagan JE, Fisher JE,
Caporale LH, Golub EE, Caulfield MP, Nutt RF, Rosenblatt M. Modifications of position 12 in parathyroid hormone and parathyroid hormone-related protein: toward the design of highly potent antagonists. Biochemistry 1990; 29:1580-1586.
81. McKee RL, Caulfield MP, Rosenblatt M. Treatment of bone-derived ROS 17/2.8 cells with
dexamethasone and pertussis toxin enables detection of partial agonist activity for parathyroid hormone antagonists. Endocrinology 1990; 127:76-82.
82. Caulfield MP, McKee RL, Goldman ME, Duong LT, Fisher JE, Gay CT, DeHaven PA, Levy JJ,
Roubini E, Nutt RF, Chorev M, Rosenblatt M. The bovine renal parathyroid hormone (PTH) receptor has equal affinity for two different amino acid sequences: the receptor binding domains of PTH and PTH-related protein are located within the 14-34 region. Endocrinology 1990; 127:83-87.
83. Nutt RF, Caulfield MP, Levy JJ, Gibbons SW, Rosenblatt M, McKee RL. Removal of partial
agonism from parathyroid hormone (PTH)-related protein-(7-34)NH2 by substitution of PTH amino acids at positions 10 and 11. Endocrinology 1990; 127:491-493.
84. Chorev M, Roubini E, Goldman ME, McKee RL, Gibbons SW, Reagan JE, Caulfield MP,
Rosenblatt M. Effects of hydrophobic substitutions at position 18 on the potency of parathyroid hormone antagonists. Int. J. Peptide Protein Res. 1990; 36:465-470.
85. Tosteson MT, Alvarez O, Hubbell W, Bieganski RM, Attenbach C, Caporale LH, Levy JJ, Nutt
RF, Rosenblatt M, Tosteson DC. Primary structure of peptides and ion channels: role of amino acid side chains in voltage gating of melittin channels. Biophys. J. 1990; 58:1367-1375.
28
86. Chorev M, Roubini E, McKee RL, Gibbons SW, Reagan JE, Goldman ME, Caulfield MP, Rosenblatt M. Biological activity of parathyroid hormone antagonists substituted at position 13. Peptides 1991; 12:57-62.
87. Chorev M, Roubini E, McKee RL, Gibbons SW, Goldman ME, Caulfield MP, Rosenblatt M.
Cyclic parathyroid hormone related protein antagonists: lysine 13 to aspartic acid 17 [i to (i + 4)] side chain to side chain lactamization. Biochemistry 1991; 30:5968-5974.
88. Caulfield M, Park K, Rosenblatt M, Fasman GD. Correlation of secondary structure with
biological activity for a leader peptide: circular dichroism-derived structure and in vitro biological activities of preproparathyroid hormone peptide and its analogs. Arch. Biochem. Biophys. 1991; 289:208-213.
89. Goud NA, McKee RL, Sardana MK, DeHaven PA, Huelar E, Syed MM, Goud RA, Gibbons
SW, Fisher JE, Levy JJ, Rodkey JA, Bennett C, Ramjit HG, Caporale LH, Caulfield M, Rosenblatt M. Solid-phase synthesis and biological activity of human parathyroid hormone(1-84). J. Bone Min. Res. 1991; 6:781-789.
90. Yamamoto M, Duong LT, Fisher J, Thiede MA, Caulfield MP, Rosenblatt M. Suckling-
mediated increases in urinary phosphate and 3',5'-cyclic adenosine monophosphate excretion in lactating rats: possible systemic effects of parathyroid hormone-related protein. Endocrinology 1991; 129:2614-2622.
91. Roubini E, Duong LT, Gibbons SW,Leu CT, Caulfield MP, Chorev M, Rosenblatt M.
Synthesis of fully active biotinylated analogues of parathyroid hormone and parathyroid hormone-related protein as tools for the characterization of parathyroid hormone receptors. Biochemistry 1992; 31:4026-4033.
92. Yamamoto M, Fisher J, Thiede MA, Caulfield MP, Rosenblatt M, Duong LT. Concentrations
of parathyroid hormone-related protein in rat milk change with duration of lactation and interval from previous suckling, but not with milk calcium. Endocrinology 1992; 130:741-747.
93. Chorev M, Caulfield MP, Roubini E, McKee RL, Gibbons SW, Leu C-T, Levy JL, Rosenblatt
M. A novel, mild, specific and indirect maleimido-based radioiodolabeling method. Radiolabeling of analogs derived from parathyroid hormone (PTH) and PTH-related protein (PTHrP). Int. J. Peptide Protein Res. 1992; 40:445-455.
94. Orloff JJ, Ribaudo AE, McKee RL, Rosenblatt M., Stewart AF. A Pharmacologic Comparison
of Parathyroid Hormone Receptors in Human Bone and Kidney. Endocrinology 1992; 131:1603-1611.
95. Fisher JE, Caulfield MP, Sato M, Quartuccio HA, Gould RJ, Garsky VM, Rodan G,
Rosenblatt M. Inhibition of Osteoclastic Bone Resorption in Vivo by Echistatin, an "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein. Endocrinology 1993; 132:1411-1413.
96. Chorev M, Epand RF, Rosenblatt M, Caulfield MP, Epand RM. Circular dichroism (CD)
studies of antagonists derived from parathyroid hormone-related protein. Int. J. Pept. Protein Res. 1993; 42:342-345.
97. Rosen H, Dresner-Pollak R, Moses A, Rosenblatt M, Zeind A, Clemens J,Greenspan S.
Specificity of urinary excretion of cross-linked N-telopeptides of Type I collagen as a marker of bone turnover. Calcified Tissue International 1994; 54:26-29.
29
98. Pines M, Adams AE, Stueckle S, Bessalle R, Rashti-Behar V, Chorev M, Rosenblatt M and
Suva LJ. Generation and characterization of human kidney cell lines stably expressing recombinant human PTH/PTHrP receptor: lack of interaction with C-terminal human PTH peptide. Endocrinology 1994; 135:1713-1716.
99. Kukreja S, Danza J, Wimbiscus S, Fisher J, McKee R, Caulfield M, and Rosenblatt M.
Inactivation by plasma may be responsible for lack of efficacy of parathyroid hormone antagonists in hypercalcemia of malignancy. Endocrinology 1994; 134: 2184-2188.
100. Rosen H., Middlebrooks V, Sullivan E, Rosenblatt M, Maitland L, Moses A, Greenspan S.
Subregion analysis of the rat femur: A sensitive indicator of changes in bone density following treatment with thyroid hormone or bisphosphonates. Calcified Tissue Int. 1994; 55: 173-175.
101. Nakamoto C, Behar V, Chin K, Adams A, Suva L, Rosenblatt M, Chorev M. Probing the
bimolecular interactions of parathyroid hormone and the human parathyroid hormone/parathyroid hormone-related protein receptor. I. Design, synthesis and characterization of photoreactive benzophenone-containing analogs of parathyroid hormone. Biochemistry 1995; 34: 10546-10552.
102. Adams A, Pines M, Nakamoto C, Behar V, Yang QM, Bessalle R, Chorev M, Rosenblatt M,
Levine M and Suva L. Probing the biomolecular interactions of parathyroid hormone and the human parathyroid hormone/parathyroid hormone-related protein receptor.II. Cloning, characterization, and photoaffinity labeling of the recombinant human receptor. Biochemistry 1995; 34: 10553-10559.
103. Chorev M, Behar V, Yang Q, Rosenblatt M, Mammi S, Maretto S, Pelligrini M, Peggion E.
Conformation of parathyroid hormone antagonists by CD, NMR and molecular dynamic simulations. Biopolymers 1995; 36:485-495.
104. Chorev M, Suva L, Nakamoto C, Yang QM, Behar V, Adams A, Chin K, Stueckle S,
Rosenblatt M. Approaches to studying the biomolecular interaction between the parathyroid hormone/parathyroid hormone-related protein receptor and its ligands. Min. Elect. Metab. 1995; 21:133-139.
105. Schetz J, Mayr C, Taylor JE, Rosenblatt M, Chorev M, Davis T. Distribution and
pharmacokinetics of a potent peptide antagonist of parathyroid hormone and parathyroid hormone-related protein in the rat. J. Phar. Exp. Ther. 1995; 274:1456-1462.
106. Pines M, Fukayama S, Costas K, Meurer P, Goldsmith PK, Xu X, Muallem S, Behar V,
Chorev M, Rosenblatt M, Tashjian AH, Suva LJ. Inositol 1-,4-,5-trisphosphate-dependent Ca2+ signaling by the recombinant human PTH/PTHrP receptor stably expressed in a human kidney cell line. Bone 1996; 18:381-389.
107. Dresner-Pollak R, Yang QM, Behar V, Nakamoto C, Chorev M, Rosenblatt M. Evaluation in
vivo of a potent parathyroid hormone antagonist: [Nle8,18, D-Trp12,Tyr34]bPTH(7-34)NH2. J Bone Min. Research 1996; 11:1061-1065.
108. Behar V, Pines M, Nakamoto C, Greenberg Z, Bisello A, Stueckle S, Bessalle R, Usdin TB,
Chorev M, Rosenblatt M and Suva LJ. The human PTH2 receptor: binding and signal transduction properties of the stably expressed recombinant receptor. Endocrinology 1996; 137:2748-2757.
30
109. Behar V, Nakamoto C, Greenberg Z, Bisello A, Suva LJ, Rosenblatt M, Chorev M. Histidine
at Position 5 Is the Specificity "Switch" between Two Parathyroid Hormone Receptor Subtypes. Endocrinology 1996; 137:4217-4224.
110. Bisello A, Greenberg Z, Behar V, Rosenblatt M, Suva L, Chorev M. Role of glycosylation in
expression and function of the human parathyroid hormone/ parathyroid hormone-related protein receptor. Biochemistry 1996; 35 (49):15890-1 5895.
111. Bisello A, Nakamoto C, Rosenblatt M, Chorev, M. Mono- and bicyclic analogs of parathyroid
hormone-related protein: 1. synthesis and biological studies. Biochemistry 1997; 36: 3293-3299.
112. Stefano M, Bissacco E, Peggion E, Bissello A, Rosenblatt M, Chorev M, Mierke D. Mono-
and bicyclic analogs of parathyroid hormone-related protein: 2. conformational analysis of antagonists by CD, NMR and distance geometry calculations. Biochemistry 1997; 36: 3300-3307.
113. Zhou A, Bessalle R, Bisello A, Nakamoto C, Rosenblatt M, Suva L, Chorev M. Direct
mapping of an agonist-binding domain within the parathyroid hormone/parathyroid hormone-related protein receptor by photoaffinity crosslinking. Proc. Natl. Acad. Sci. USA, 1997; 94:3644-3649.
114. Mierke DF, Maretto S, Schievano E, DeLuca D, Bisello A, Mammi S, Rosenblatt M, Peggion
E, Chorev M. Conformational Studies of Mono- and Bicyclic Parathyroid Hormone-Related Protein-Derived Agonists. Biochemistry 1997; 36:10372-1383.
115. Pellegrini M, Bisello A, Rosenblatt M, Chorev M, Mierke DF. Conformational studies of RS-
66271, an analog of parathyroid hormone-related protein with pronounced bone anabolic activity. J. Medicinal Chemistry 1997; 40:3025-3031.
116. Suva LJ, Flannery MS, Caulfield MP, Findlay DM, Juppner H, Goldring SR, Rosenblatt M,
Chorev M. Design, synthesis and utility of novel benzophenone-containing calcitonin analogs for photoaffinity labeling the calcitonin receptor. J. Pharm. Exp. Ther. 1997; 283:876-88.
117. Rosen HN, Lim M, Garber J, Moreau S, Bhargava HN, Pallotta J, Spark R, Greenspan S,
Rosenblatt M, Chorev M. The effect of PTH antagonist BIM-44002 on serum calcium and PTH levels in hypercalcemic hyperparathyroid patients. Calcif. Tissue Int. 1997; 61:455-459.
118. Fukayama S, Royo M, Sugita M, Imrich A, Chorev M, Suva LJ, Rosenblatt M, Tashjian Jr,
AH. New insights into interactions between the human PTH/PTHrP receptor and agonist/antagonist binding. Am. J. Physiology (Endocrinology and Metabolism 37) 1998; 274:E297-E303.
119. Pellegrini M, Royo M, Rosenblatt M, Chorev M, Mierke DF. Addressing the tertiary structure
of human parathyroid hormone (1-34). J. Biol.Chem. 1998; 273:10420-10427. 120. Bisello A, Adams AE, Mierke DF, Pellegrini M, Rosenblatt M, Suva LJ, Chorev M.
Parathyroid hormone--receptor interactions identified directly by photocross-linking and molecular modeling studies. J. Biol. Chem. 1998; 273:22498-22505.
31
121. Maretto S, Schievano E, Mammi S, Bisello A, Nakamoto C, Rosenblatt M, Chorev M, Peggion E. Conformational studies of a potent Leu11, D-Trp12-containing lactam-bridged parathyroid hormone-related protein-derived antagonist. J. Peptide Res., 1998; 52:241-248.
122. Pellegrini M, Bisello A, Rosenblatt M, Chorev M, Mierke Dale F. Binding domain of human
parathyroid hormone receptor: from conformation to function. Biochemistry, 1998; 37:12737-12743.
123. Adams AE, Bisello A, Chorev M, Rosenblatt M, Suva LJ. Argine 186 in the extra-cellular N-
terminal region of the human parathyroid hormone 1 receptor is essential for contact with position 13 of the hormone. J. Mol. Endo. 1998; 12:1673-1683.
124. Greenberg Z, Stoch SA, Traianedes K, Teng H, Rosenblatt M, Chorev M. Covalent
immobilization of recombinant human αvβ3 integrin on a solid support with retention of functionality. Anal. Biochem. 1999; 266:153-164.
125. Bitan G, Scheibler L, Greenberg Z, Rosenblatt M, Chorev M. Mapping the integrin αvβ3
Ligand interface by photoaffinity cross-linking. Biochemistry 1999; 38:3414-3420. 126. Adams AE, Rosenblatt M, Suva L. Identification of a novel parathyroid hormone-responsive
gene in human osteoblastic cells. Bone 1999;24:305-313. 127. Schievano E, Mammi S, Bisello A, Rosenblatt M, Chorev M, Peggion E. Conformational
studies of a bicyclic, lactam-constrained parathyroid hormone-related protein-derived agonist. J. Pep. Sci. 1999; 5:330-337.
128. Bisello A, Behar V, Greenberg Z, Suva LJ, Rosenblatt M, Chorev M. Development of a
photoreactive parathyroid hormone antagonist to probe antagonist-receptor bimolecular interaction. J. Pep. Res. 1999; 54:120-128.
129. Behar V, Bisello A, Rosenblatt M, Chorev M. Direct identification of two contact sites for
parathyroid hormone (PTH) in the novel PTH-2 receptor using photoaffinity cross-linking. Endocrinology 1999; 140:4251-4261.
130. Ferrari SL, Behar V, Chorev M, Rosenblatt M, Bisello A. Endocytosis of ligand-human
Parathyroid hormone receptor 1 complexes is protein kinase C-dependent -arrestin2. J. Biol. Chem. 1999; 274:29968-29975.
131. Peggion E, Mammi S, Schievano E, Behar V, Rosenblatt M, Chorev M. Conformational
studies of parathyroid hormone (PTH)/PTH-related protein (PTHrP) point-mutated hybrids. Biopolymers 1999; 50:525-535.
132. Behar V, Bisello A, Rosenblatt M, Chorev M. Photoaffinity cross-linking identifies differences
in the interactions of an agonist and an antagonist with the parathyroid hormone/parathyroid hormone-related receptor. J. Biol. Chem. 2000; 275:9-17.
133. Bitan G, Scheibler L, Teng H, Rosenblatt M, Chorev M. Design and evaluation of
benzophenone-containing conformationally constrained ligands as tools for photoaffinity scanning of the integrin alpha (v) beta (3)- ligand bimolecular interaction. J. Peptide Research 2000; 55:181-194.
32
134. Han Y, Bissello A, Nakamoto C, Rosenblatt M, Chorev M. 3-(3’-fluorenyl-9’-oxo)-L-alanine: a novel photoreactive conformationally constrained amino acid. J. Peptide Research 2000; 55:230-239.
135. Greenberg Z, Bisello A, Mierke D F, Rosenblatt M, Chorev M. Mapping the bimolecular
interface of the parathyroid hormone (PTH)-PTH1 receptor complex: spatial proximity between Lys27 (of the hormone principal binding domain) and Leu261 (of the first extracellular loop) of the human PTH1 receptor. Biochemistry 2000; 39:8142-8152.
136. Bitan G, Scheibler L, Mierke D F, Rosenblatt M, Chorev M. Ligand-Integrin v3 interaction determined by photoaffinity cross-linking: A challenge to the prevailing model. Biochemistry 2000; 39:11014-11023.
137. Ferrari S L, Traianedes K, Thorne M, LaFage-Proust M H, Genever P, Cecchini M G, Behar
V, Bisello A, Chorev M, Rosenblatt, M, Suva L J. A role for N-Cadherin in the development of the differentiated osteoblastic phenotype. J. Bone Mineral Res 2000; 15:198-208.
138. Schievano E, Mammi S, Silvestri L, Behar V, Rosenblatt M, Chorev M, Peggion E.
Conformational studies of parathyroid hormone (PTH)/PTH-related protein (PTHrP) chimeric peptides. Bioploymers, 2000; 54:429-447.
139. Piserchio A, Bisello A, Rosenblatt M, Chorev M, Mierke DF. Characterization of parathyroid
hormone/receptor interactions: structure of the first extracellular loop. Biochemistry. 2000; 39:8153-8160.
140. Scheibler L, Mierke D F, Bitan G, Rosenblatt M, Chorev M. Identification of a contact domain
between echistatin and the integrin αvβ3 by photoaffinity crosslinking. Biochemistry, 2001; 40:15117-15126.
141. Alexander JM, Bab I, Fish S, Muller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q,
White D W, Chorev M, Gazit D, and Rosenblatt M. Human parathyroid hormone 1—34 reverses bone loss in ovariectomized mice. J. Bone and Mineral Research 2001; 16: 1665-1673.
142. Royo M, Van Den Nest W, del Fresno M, Frieden A, Yahalom D, Rosenblatt M, Chorev M,
Albericio F. Solid-phase syntheses of constrained RGD scaffolds and their binding to the αvβ3 integrin receptor. Tetrahedron Letters 2001; 42: 7387-7391.
143. Yahalom D, Wittelsberger A, Miercke DF, Rosenblatt M, Alexander JM, Chorev M.
Identification of the principal binding site for RGD-containing ligands in the αvβ3 integrin: a photoaffinity cross-linking study. Biochemistry 2002; 41: 8321-8331.
144. Peggion E, Mammi S, Schievano E, Schiebler L, Corich M, Rosenblatt M, Chorev M.
Structure-function relationship studies of bovine parathyroid hormone [bPTH(1-34)] analogues containing α-amino-iso-butyric acid (aib) residues. Biopolymers 2003; 68: 437-457.
145. Peggion E, Mammi S, Schievano E, Silvestri L, Schiebler L, Bisello A, Rosenblatt M, Chorev
M. Structure-function studies of analogues of parathyroid hormone (PTH)-1-34 containing β-amino acid residues in positions 11-13. Biochemistry 2002; 41: 8162-8175.
33
146. Bisello A, Chorev M, Rosenblatt M, Monticelli L, Mierke DF, Ferrari SL. Selective ligand-induced stabilization of active and desensitized parathyroid hormone type 1 receptor conformations. J Biol Chem 2002; 277: 38524-38530.
147. Rosenblatt M. Is it ethical to conduct placebo-controlled clinical trials in the development of
new agents for osteoporosis? An industry perspective. J of Bone and Mineral Research 2003; 18: 1142-1145.
148. Schievano E, Mammi S, Carretta E, Fiori N, Corich M, Bisello A, Rosenblatt M, Chorev M,
Peggion E. Conformational and biological characterization of human parathyroid hormone hPTH(1-34) analogues containing beta-amino acid residues in positions 17-19. Biopolymers 2003; 70: 534-547.
149. Rosen HN, Parker RA, Greenspan SL, Iloputaife ID, Bookman L, Chapin D, Perlmutter I,
Kessel B, Qvist P, Rosenblatt M. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT. Calcified Tissue International 2004; 74: 415-423.
150. Barazza A, Wittelsberger A, Fiori N, Schievano E, Mammi S, Toniolo C, Alexander JM,
Rosenblatt M, Peggion E, Chorev M. Bioactive N-terminal undecapeptides derived from parathyroid hormone: the role of α-helicity. J. Peptide Res. 2005; 65: 23-35.
151. Kuperwasser C, Dessain S, Bierbaum BE, Garnet D, Sperandio K, Gauvin GP, Naber SP,
Weinberg RA, Rosenblatt M. A mouse model of human breast cancer metastasis to human bone. Cancer Research 2005; 65: 6130-6138.
152. Scian M, Marin M, Bellanda M, Tou L, Alexander JM, Rosenblatt M, Chorev M, Peggion E,
Mammi S. Backbone dynamics of human parathyroid hormone (1-34): flexibility of the central region under different environmental conditions. Peptide Science 2005; 84: 147-160.
153. Gan L, Alexander JM, Wittelsberger A, Thomas B, Rosenblatt M. Large-scale purification and
characterization of human parathyroid hormone-1 receptor stably expressed in HEK293S GnTI¯ cells. Protein Expr. Purif. 2006; 47: 296-302.
154. Wittelsberger A, Corich M, Thomas BE, Lee BK, Barazza A, Czodrowski P, Mierke DF,
Chorev M, Rosenblatt M. The mid-region of parathyroid hormone (1-34) serves as a functional docking domain in receptor activation. Biochemistry 2006; 45: 2027-2034.
155. Wittelsberger A, Thomas B, Mierke D, Rosenblatt M. Methionine acts as a "magnet" in
photoaffinity crosslinking experiments. FEBS Letters 2006; 580: 1872-1876. 156. Thomas BE, Wittelsberger A, Woznica I, Hsieh M, Monaghan P, Lee BK, Rosenblatt M.
Cysteine at position 217 in the intracellular loop 1 plays a critical role in human parathyroid hormone receptor type 1 membrane translocation and function. J of Bone and Mineral Research 2007; 22: 609-616.
157. Monaghan P, Woznica I, Moza B, Sundberg EJ, Rosenblatt, M. Recombinant expression and
purification of the N-terminal extracellular domain of the parathyroid hormone receptor. Protein Expr. Purif. 2007; 54:87-93.
34
158. Moreau JE, Anderson K, Mauney JR, Nguyen T, Kaplan DL, Rosenblatt M. Tissue-engineered bone serves as a target for metastasis of human breast cancer in a mouse model. Cancer Research 2007; 67:10304-10308.
159. Thomas BE, Woznica I, Mierke DF, Wittelsberger A, Rosenblatt M. Conformational changes
in the parathyroid hormone receptor associated with activation by agonist. Mol Endocrinol. 2008; 22(5):1154-1162.
160. Wittelsberger A, Mierke DF, Rosenblatt M. Mapping ligand—receptor interfaces: approaching
the resolution limit of benzophenone-based photoaffinity scanning. Chem Biol Drug Des. 2008; 71 (4):380-383.
161. Monaghan P, Thomas B, Woznica I, Wittelsberger A, Mierke D, Rosenblatt, M. Mapping
peptide hormone—receptor interactions using a disulfide-trapping approach. Biochemistry 2008; 47 (22):5889-95.
162. Thomas BE, Sharma S, Mierke DF, Rosenblatt M. Parathyroid hormone (PTH) and PTH
antagonist induce different conformational changes in the PTHR1 receptor. J Bone and Mineral Research 2009; 24:925-934.
163. Liu S, Goldstein RH, Scepansky EM, Rosenblatt M. Inhibition of Rho-associated kinase
signaling prevents breast cancer metastasis to human bone. Cancer Res 2009; 69:8742-8751
164. Goldstein RH, Reagan MR, Anderson K, Kaplan DL,Rosenblatt M. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer Research 2010;70(24):10044-50
165. Walt, David R.; Kuhlik, Amy; Epstein, Scott K.; Demmer, Laurie A.; Knight, Meredith;
Chelmow, David; Rosenblatt, Michael; Bianchi, Diana W., Lessons learned from the introduction of personalized genotyping into a medical school curriculum. Genetics in Medicine 2011;13(1):63-66
Peer-Reviewed Commentaries: 1. Powell D, Scott J L, Rosenblatt M, Roth P B, Pololi L. Commentary: “A Call for Culture Change
in Academic Medicine.” Academic Medicine, Vol. 85, No. 4, April 2010.
2. Goldstein RH, Weinberg RA, Rosenblatt M. Of Mice and (Wo)men: Mouse Models of Breast Cancer Metastasis to Bone. J Bone and Mineral Research 2010; 25: 431–436
3. Scepansky EM, Rosenblatt M. "Pre-clinical Orthotopic and Intracardiac Injection Models of
Human Breast Cancer Metastasis to Bone and their Use in Drug Discovery." Curr. Protoc. Pharmacol;. 52:14.18.1-14.18.23. by John Wiley & Sons, Inc., 2011
4. Morris, SA, Lewis-Hall, F, Orloff, J, Rosenblatt, M, Waldstreicher, J, "The PCAST Report: Impact and Implications for the Pharmaceutical Industry" Clinical Pharmacology & Therapeutics 2013; 94 3, 300–302.
5. Jain S, Rosenblatt M, Duke J, “Is Big Data the New Frontier for Academic-Industry Collaboration,” JAMA June 04, 2014: Volume 311, Number 21.
35
6. Rosenblatt, M, “How a Public-Private Partnership Is Saving Lives,” Harvard Business Review, Harvard Business Review Blog Network, May 5, 2014.
7. Rosenblatt, M, “The Real Cost of High-Priced Drugs,” HBR-NEJM Insight Center, Harvard
Business Review Blog Network, November 17, 2014. 8. Brenner, J, Rosenblatt M, “Transforming healthcare one patient at a time,” The Hill, December
08, 2014.
9. Rosenblatt M, Jain S, Cahill M, “Sharing of Clinical Trial Data: Benefits, Risks, and Uniform Principles.” Ann Intern Med 2015; 162(4):306-307.
10. Rosenblatt M; Kuhlik, B, “Principles and Challenges in Access to Experimental
Medicines.” JAMA 2015; 313(20):2023-2024, May 26, 2015.
11. Rosenblatt M, “Challenges in Clinical Trials Research from the Large Pharmaceutical Company Perspective.” New England Journal of Medicine, (accepted for publication in 2016).
Editorials/Letters to Editor 1. Kim, P, Rosenblatt, M, “Response to Drazen: ‘Don't mess with the DSMB’” July 7, 2010, N
Engl J Med 2011; 364:1879-1880, May 12, 2011.
2. Berman, Harris A, Rosenblatt M, “Prescription for national health: get patients to take their medicine.” Boston Globe, April 17, 2012.
3. Rosenblatt, M, “Statement to The Editor, Huffington Post in response to ‘Side Effects May
Include Death: The Story Of The Biggest Advance In Birth Control Since The Pill’”, Huffington Post, December 19, 2013.
4. Barron, H, Rosenblatt, M, “To the Editor” in response to “Access to Patient-Level Trial Data,”
October 24, 2013, N Engl J Med 2014; 370:485-486, January 30, 2014.
Proceedings of Meetings:
1. Rosenblatt M, D'Amour P, Segre GV, Potts JT Jr. Synthesis of a fragment of bovine
parathyroid hormone, bPTH-(28--48): an inhibitor of hormone cleavage in vivo. In: Goodman M, Meienhofer J, eds. Peptides - 1977; Proceedings of the Fifth American Peptide Symposium. New York: John Wiley & Sons, Inc., 1977:232-235.
2. Rosenblatt M, Mahaffey JE, Potts JT Jr. Parathyroid hormone inhibitors: design, synthesis,
and biological evaluation. In: Goodman M, Meienhofer, J, eds. Peptides 1977; Proceedings of the Fifth American Peptide Symposium. New York: John Wiley & Sons, Inc., 1977: 581-583.
3. Segre GV, D'Amour P, Rosenblatt M, Potts JT Jr. Heterogeneity and metabolism of
parathyroid hormone. In: Copp DH, Talmage RV, eds. Endocrinology of Calcium Metabolism. Proceedings of the Sixth Parathyroid Conference, Vancouver, June 12-17, 1977. Amsterdam: Excerpta Medica (ICS 421), 1978:329-332.
36
4. Rosenblatt M, Majzoub JA, Kronenberg HM, Habener JF, Potts JT Jr. The precursor-specific region of pre-proparathyroid hormone: chemical synthesis and preliminary studies of its effect on post-translational modification of hormone. In: Gross E, Meienhofer J, eds. Peptides: Structure and Biological Function; Proceedings of the Sixth American Peptide Symposium. Rockford, IL: Pierce Chemical Co., 1979:535-538.
5. Rosenblatt M, Segre GV, Shepard GL, Tyler GA, Nussbaum SR, Potts JT Jr. Binding to the
parathyroid hormone receptor: delineation of structural determinants in the amino-terminal region of the molecule necessary for binding. In: Gross E, Meienhofer J, eds. Peptides: Structure and Biological Function; Proceedings of the Sixth American Peptide Symposium. Rockford, IL: Pierce Chemical Co., 1979:1025-1028.
6. Tregear GW, Veroni MC, Rosenblatt M, Shepard GL, Tyler GA, Potts JT Jr. Solid-phase
synthesis of the 32-amino acid carboxyl-terminal fragment of human parathyroid hormone hPTH (53--84): comparison of strategies. In: Gross E, Meienhofer J, eds. Peptides: Structure and Biological Function; Proceedings of the Sixth American Peptide Symposium. Rockford, IL: Pierce Chemical Co., 1979:357-360.
7. Potts JT Jr, Habener JF, Segre GV, Kronenberg HM, Rosenblatt M. Calcium homeostasis:
biosynthesis, metabolism and mode of action of parathyroid hormone. In: Cumming IA, Funder JW, Mendelsohn FAO, eds. Endocrinology; Proceedings of the VI International Congress of Endocrinology, Melbourne, Australia, Feb. 10-16, 1980). Amsterdam: Australian Academy of Science and Elsevier/North-Holland, 1980:35-42.
8. Nussbaum SR, Rosenblatt M, Mudgett-Hunter M, Potts JT Jr. Monoclonal antibodies directed
against the biologically active region of parathyroid hormone. In: Fellow R, Eisenbarth G, eds. Monoclonal Antibodies in Endocrine Research; Proceedings of the NIH Workshop on Monoclonal Antibodies. New York: Raven Press, 1981:181-192.
9. Rosenblatt M, Majzoub JA, Beaudette NV, Kronenberg HM, Potts JT Jr, Fasman GD,
Habener JF. Chemically synthesized precursor-specific fragment of pre-proparathyroid hormone: conformational and biological properties. In: Brunfeldt K, ed. Peptides 1980; Proceedings of the 16th European Peptide Symposium, Aug. 31-Sept. 6, 1980. Copenhagen: Scriptor, 1981: 572-577.
10. Rosenblatt M, Nussbaum SR, Potts JT Jr. Demonstration and relative importance of two
binding regions for parathyroid hormone. In: Brunfeldt K, ed. Peptides 1980 Proceedings of the 16th European Peptide Symposium, Aug. 31-Sept. 6, 1980. Copenhagen: Scriptor, 1981:578-583.
11. Rosenblatt M. Mechanisms of parathyroid hormone action. In: Rich DH, Gross E, eds.
Peptides: Synthesis-Structure-Function; Proceedings of the Seventh American Peptide Symposium. Rockford, IL: Pierce Chemical Co., 1981:789-791.
12. Rosenblatt M. The parathyroid hormone molecule: biological implications. Proc. Fifth
International Workshop on Phosphates, 1981. Adv. Exp. Biol. Med. 1982:151:521-534. 13. Rosenblatt M. Control of parathyroid hormone secretion. Proceedings: Heidelberg Seminars
Nephrol.) Contrib. Nephrol.1982; 33:163-177.
37
14. Nussbaum SR, Shuldiner AR, Rosenblatt M. Binding of alpha-MSH and structurally-related peptides to rat-brain opiate receptors. In: Hruby VJ, Rich DH, eds. Peptides 1983; Proc. 8th American Peptide Symposium. Rockford, IL: Pierce Chemical Co., 1983:429-432.
15. Rosenblatt M. Studies of parathyroid hormone-receptor interactions: design of an antagonist
effective in vivo and photoaffinity labeling of parathyroid hormone. Hruby VJ, Rich DH, eds. Proceedings of the 8th American Peptide Symposium. Rockford, IL: Pierce Chemical Co., 1983:631-640.
16. Rosenblatt M, Horiuchi N, Doppelt S, Tyler GA, Goldring SR, Holick MF, Krane SM,
Neer RM, Potts JT Jr. Parathyroid hormone - receptor interactions: characterization of receptors and development of inhibitors effective in vivo. In: Cohn DV, Fujita T, Potts JT Jr, Talmage RV, eds. Endocrine Control of Bone and Calcium Metabolism, Vol. 8A. Proceedings of the Eighth International Conference on Calcium Regulating Hormones, Kobe, Japan, October 16-24, 1983. Elsevier Science Publishers B.V., 1984:209-216.
17. Rosenblatt M, Tyler GA, Doppelt SH, Horiuchi N, Neer RM, Potts JT Jr. The design and
biological evaluation of a parathyroid hormone antagonist effective in vivo. Proceedings of the Seventh International Congress of Endocrinology, Quebec City, Canada, (July 1-7, 1984). In: Labrie F, Proulx L, eds. Endocrinology, Elsevier Science Publishers B.V., 1984: 579-582.
18. Pang PKT, Nussbaum SR, Rosenblatt M. Vascular actions of bovine parathyroid hormone
fragments. In: Lofts B, Holmes W., eds. Current Trends in Comparative Endocrinology, Vol 2. Proceedings of the 9th International Symposium on Comparative Endocrinology, December 7-11, 1981. Hong Kong: Hong Kong University Press, 1985:1993-995.
19. Caporale L, DeHaven P. Fisher J, Tyler G, Rosenblatt M. Discrimination between parathyroid
hormone (PTH) agonists and antagonists in vitro: modification of the renal membrane adenylate cyclase assay to reflect in vivo activity of PTH analogs. In: Deber CM, Hruby VJ, Kopple KD, eds., Peptides: Structure and Function; Proceedings of the Ninth American Peptide Symposium, Toronto, Canada, June 23-28, 1985. Rockford: Pierce Chemical Company, 1985: 663-666.
20. Hirschmann R., Rosenblatt M. Atrial natriuretic factors. Introductory remarks and preliminary
clinical results. In: Deber CM, Hruby VJ, Kopple KD, eds. Peptides: Structure and Function; Proceedings of the Ninth American Peptide Symposium, Rockford: Pierce Chemical Company, 1985:907-908.
21. Caporale L, Nutt R, Levy J, Rosenblatt M, Smith J, Arison B, Randall W, Bennett C, Albers-
Schonberg G, Pitzenberger S, Hirschmann R. Characterization of synthetic peptide hormone analogs and of byproducts. (Proceedings of the 19th European Peptide Symposium, Chalkidiiki, Greece 8/31-9/5/86.) In: Theodoropoulos D, ed. Peptides, Berlin, Germany: Walter de Gruyter & Co., 1987:223-226.
22. Caporale LH, Chorev M, Levy JJ, Goldman ME, DeHaven PA, Gay CT, Reagan JE,
Rosenblatt M, Nutt, RF. Characterization of parathyroid hormone antagonists. (Proceedings of the Tenth American Peptide Symposium, May 23-28, 1987, St. Louis, Missouri.) In: Marshall GR, Peptides: Chemistry and Biology, Leiden: Escom, 1988:449-451.
23. Rosenblatt M, Caulfield MP, Fisher JE, Horiuchi N, McKee RL, Rodan SB, Thiede MA,
Thompson DD, Seedor JG, Nutt RE, Goldman ME, Reagan JE, Levy JJ, Gay CT, DeHaven PA, Strewler GJ, Nissenson RA, Clemens TL, Rodan GA. A tumor-secreted protein
38
associated with human hypercalcemia of malignancy. Biology and molecular biology. In: Endocrine, Metabolic and Immunologic Functions of Keratinocytes, Vol. 548 of Annals of the New York Academy of Sciences, 1988:137-145.
24. Chorev M, Goldman ME, Caporale LH, Levy JJ, Reagan JE, DeHaven P, Gay T, Nutt RF,
Rosenblatt M. Probing of the conformation of a parathyroid hormone agonist (1--34) and antagonist (7--34) by studying the effect of single amino acid substitutions on biological activity. (1st Japan Symposium on Peptide Chemistry, Kobe, Japan, September 28-October 2, 1987.) In: Shiba T, Sakakibara S., eds., Peptide Chemistry 1987, Osaka: Protein Research Foundation, 1988: 621-626.
25. Rosenblatt M, Caulfield MP, Fisher JE, Horiuchi N, McKee RL, Rodan SB, Thiede MA,
Thompson DD, Seedor JG, Nutt RE, Goldman ME, Reagan JE, Levy JJ, Gay CT, DeHaven PA, Strewler GJ, Nissenson RA, Clemens TL, Rodan, GA. A tumor-secreted protein associated with human hypercalcemia of malignancy. Biology and molecular biology. Endocrine, Metabolic and Immunologic Functions of Keratinocytes, Vol. 548, Annals of the New York Academy of Sciences 1988: 137-145.
26. Caulfield MP, Duong LT, Rosenblatt M. Synthetic signal peptides of parathyroid hormone:
probes for components of the secretory apparatus. Proceedings of the First International Conference on New Actions of Parathyroid Hormone, October 1987, Kobe, Japan. In: Massry SG, Fujita T, eds., New Actions of Parathyroid Hormone, New York: Plenum Press, 1989:19-27.
27. Rosenblatt M, Chorev M, Nutt RF, Caulfield MP, Horiuchi N, Clemens TL, Goldman ME,
McKee RL, Caporale LH, Fisher JE, Levy JJ, Reagan JE, Gay T, DeHaven P. New directions for the design of parathyroid hormone antagonists. Proceedings of the First International Conference on New Actions of Parathyroid Hormone, October 1987, Kobe, Japan. In: Massry SG, Fujita T, eds., New Actions of Parathyroid Hormone, NewYork: Plenum Press, 1989: 61-67.
28. Rodan GA, Thiede M, Thompson DD, Noda M, Rodan SB, Rosenblatt M. PTH-like tumor
hypercalcemia factor. (Proceedings of the First International Conference on New Actions of Parathyroid Hormone, October 1987, Kobe, Japan.) In: Massry SG, Fujita T, eds., New Actions of Parathyroid Hormone, New York: Plenum Press, 1989:95-99.
29. Chorev M, Goldman ME, Roubini E, Reagan JE, Levy JJ, Nutt RF, Caulfield MP, Rosenblatt
M. Second generation of potent parathyroid hormone (PTH) antagonists. Proceedings of the Eleventh American Peptide Symposium, July 1989, La Jolla, California. In: Rivier JE, Marshall GR, eds., Peptides: Chemistry, Structure and Biology, Leiden: Escom, 1990:163-164.
30. Caulfield MP, McKee RL, Goldman ME, Thiede MA, Thompson DD, Fisher JE, Levy JJ,
Seedor JG, Horiuchi N, Clemens TL, Rodan GA, Rosenblatt M. Parathyroid hormone-related protein (PTHrP): studies with synthetic peptides indicate that parathyroid hormone and PTHrP interact with the same receptor. Nucl. Med. Biol. 1990: 17:633-637.
31. Thompson DD, Weinreb M, Seedor JG, Fisher JE, Rosenblatt M, Rodan GA. Comparison of
the histomorphometric effects of the parathyroid hormone-like hypercalcemia peptide (hHCF) and parathyroid hormone (PTH) on vertebrae in rats. (Proceedings of the Fifth International Congress on Bone Morphometry, July 1988, Niigata, Japan.) In: Takahashi HE, ed., Bone
39
Morphometry, Nishimura Co., Ltd., Niigata, London, U.K.: Japan and Smith-Gordon and Co., Ltd., 1990:298-300.
32. Pellegrini M, Bisello A, Rosenblatt M, Chorev M, Mierke DF. RS-66271, a clinical candidate
derived from parathyroid hormone related protein: The role of enhanced amphiphilic helicity. The Fifteenth American Peptide Symposium, June 1997, Nashville, Tennessee. In: Tam J., Kaumaya PTP, eds., Peptides: Frontiers of Peptide Science. 1998:392-393.
33. Pellegrini M, Maretto S, Royo M, Rosenblatt M, Chorev M, Mierke D. Secondary and tertiary
fold of the human parathyroid hormone 1-34 in different environments as a pathway to bioactive conformation. The Fifteenth American Peptide Symposium, June 1997, Nashville, Tennessee. In: Tam J., Kaumaya PTP, eds., Peptides: Frontiers of Peptide Science. 1998:402-403.
34. Maretto S, Schievano E, Peggion E, Mammi S, Bisello A, Chorev M, Rosenblatt M, Mierke D.
Parathyroid hormone-related protein derived mono-and bicyclic agonists and antagonists: A conformational comparison. The Fifteenth American Peptide Symposium, June 1997, Nashville, Tennessee. In: Tam J., Kaumaya PTP, eds., Peptides: Frontiers of Peptide Science. 1998:439-440.
35. Bitan G, Pellegrini M, Chorev M, Mierke D. Lactam cyclization [I to (I+4)] for
nucleation/stabilization of α-helices? The Fifteenth American Peptide Symposium, June 1997, Nashville, Tennessee. In: Tam J., Kaumaya PTP, eds., Peptides: Frontiers of Peptide Science. 1998:451-452.
36. Mammi S, Pauletto L, Peggion E, Behar V, Rosenblatt M, Chorev M. Conformational studies
of PTH/PTHrP hybrids. The Fifteenth American Peptide Symposium, June 1997, Nashville, Tennessee. In: Tam J., Kaumaya PTP, eds., Peptides: Frontiers of Peptide Science. 1998:447-448.
37. Maretto S, Schievano E, Mammi S, Bisello A, Nakamoto C, Rosenblatt M, Chorev M,
Peggion E. Conformational studies of a D-Trp12-substituted PTHrP-derived antagonist containing lactam-bridged side-chains. The Fifteenth American Peptide Symposium, June 1997, Nashville, Tennessee. In: Tam J., Kaumaya PTP, eds., Peptides: Frontiers of Peptide Science. 1998:479-480.
38. Dong JZ, Nakamoto C, Chorev M, Morgan B, Rosenblatt M, Moreau JP. Highly potent
human parathyroid hormone analogs. The Fifteenth American Peptide Symposium, June 1997, Nashville, Tennessee. In: Tam J., Kaumaya PTP, eds., Peptides: Frontiers of Peptide Science. 1998: 541-542.
39. Barazza A, Fiori N, Schievano E, Mammi S, Peggion E, Alexander JM, Rosenblatt M, Chorev
M. Bioactive N-terminal undecapeptides derived from parathyroid hormone PTH. The role of α-helicity. In Peptide Revolution: Genomics, Proteomics & Therapeutics. Proceedings of the Eighteenth American Peptide Symposium. Chorev M, Sawyer T, Eds. American Peptide Society: Cardiff CA, 2004; 673-674.
40. Wittelsberger A, Thomas BE, Mierke DF, Rosenblatt M. A Methionine Scan of Region [168-
176] of the Parathyroid Hormone Receptor 1 – The “Magnet Effect”. In Understanding Biology Using Peptides. Proceedings of the Nineteenth American Peptide Symposium. Blondelle SE, Ed. Springer, 2006; 351-352.
40
41. Moreau J, Anderson K, Mauney J, Kaplan K, Rosenblatt, M. Studies of Osteotropism on Both Sides of the Breast Cancer--Bone Section. Ann N Y Acad Sci, 2007; 1117:328-344.
42. Rosenblatt M. A Tale of Mice and (Wo)men: Development of and Insights from an "All Human" Animal Model of Breast Cancer Metastasis to Bone. American Clinical and Climatological Association. Trans Am Clin Climatol Assoc 2012; 123: 135-151
43. Califf, Robert M, Filerman, Gary L., Murray, Richard K, Rosenblatt, M, "The Clinical Trials
Enterprise in the United States: A Call for Disruptive Innovation," IOM (Institute of Medicine). April 13, 2012. Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020: Workshop Summary. Washington, DC:The National Academies Press
44. Rosenblatt M. How Academia and the Pharmaceutical Industry Can Work Together.
Proceedings of the American Thoracic Society. Ann Am Thorac Soc 2013 Feb;10(1):31-38* *Most cited reference in 2013 for this journal
Reviews, Chapters in Books, and Books: 1. Rosenblatt M. Parathyroid hormone: chemistry and structure-activity relations. Pathobiol.
Annu. 1981; 11:53-86. 2. Potts JT Jr, Kronenberg HM, Rosenblatt M. Parathyroid hormone: chemistry, biosynthesis,
and mode of action. Adv. Protein Chem. 1982; 35:323-396. 3. Rosenblatt M. Pre-proparathyroid hormone, proparathyroid hormone, and parathyroid
hormone: the biologic role of hormone structure. Clin. Orthop. Rel. Res. 1982; 170:260-276. 4. Rosenblatt M. Pre-proparathyroid hormone: intracellular transport and processing. Mineral
Electrolyte Metab.1982; 8:118-129. 5. Rosenblatt M. Structure-activity relations in the calcium-regulating peptide hormones. In:
Parsons JA, ed. Endocrinology of Calcium Metabolism. (Martini L, series ed. Comprehensive Endocrinology), New York: Raven Press, 1982:103-142.
6. Rosenblatt M. The Endorphins--The Body's Own Opiates. Harvard Medical School Health
Letter, January 1983; Vol. VIII, No. 3. 7. Rosenblatt M. Neuropeptides: future implications for medicine. Medical Times 1983;
111:31-37. 8. Rosenblatt M. Neuropeptides: future implications for medicine. Resident & Staff Physician
1984; 30:52-72. 9. Rosenblatt M. Parathyroid Hormone: intracellular transport, secretion, and receptor
interaction. Peptide Protein Rev. 1984; 2:209-296. 10. Carr DB, Rosenblatt M. Endorphins in the normal and abnormal pituitary. Proceedings of the
International Symposium on Pituitary Tumors, June 1983. In: P. McL. Black et al. eds. Secretory Tumors of the Pituitary Gland, (Progress in Endocrine Research and Therapy, Vol. 1). New York: Raven Press, 1984:245-261.
41
11. Habener JF, Rosenblatt M, Potts JT Jr. Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism. Physiol. Rev. 1984; 64:985-1053.
12. Rosenblatt M. Endocrinology. General introduction. In: Smith LH Jr, Thier SO, eds.
Pathophysiology. The Biological Basis of Disease, 2nd Ed. Philadelphia: W.B. Saunders Company, 1985:487-495.
13. Rosenblatt M. Hormonal regulation of calcium metabolism. In: Smith LH Jr, Thier SO, eds.
Pathophysiology. The Biological Basis of Disease, 2nd Edition. Philadelphia: W.B. Saunders Company, 1985:597-610.
14. Nussbaum SR, Lin CS, Potts JT Jr, Rosenthal AS, Rosenblatt M. Development of
monoclonal antibodies against parathyroid hormone: genetic control of the immune response to human PTH. In: Colowick SP, Kaplan NO, eds. Methods in Enzymology, Vol 109, Hormone Action, Part 1. Orlando, Florida: Peptide Hormones, Academic Press, Inc., 1985:625-639.
15. Rosenblatt M. Peptide hormone antagonists that are effective in vivo: lessons from
parathyroid hormone. Beth Israel Seminar in Medicine. New Eng. J. Med 1986; 315:1004-1013.
16. Copeland PA, Fitzgerald PA, Rosenblatt M. Adrenal disorders. In: Fitzgerald PA, ed.
Handbook of Clinical Endocrinology, Chapter 6. Greenbrae, California: Jones Medical Publications, 1986:170-203.
17. Caporale LH and Rosenblatt M. Parathyroid hormone secretion. Contr. Nephrol. Basel,
Switzerland: S. Karger, 1986; 50:73-95. 18. Caporale LH and Rosenblatt M. Parathyroid hormone antagonists effective in vivo. In Masey
SG, Olmer M, Ritz E, eds., Phosphate and Mineral Homeostasis, Plenum Press Publishing Corp., 1986:315-327.
19. Rosenblatt M. The endogenous opiate peptides (Chapter 69). In: Braunwald E, Isselbacher
KJ, Petersdorf RG, Wilson JD, Martin JB, Fauci AS, eds. Harrison's Principles of Internal Medicine, 11th Edition. McGraw-Hill Book Company, 1987:378-382.
20. Rosenblatt M, Jacobs JW (Guest Editors). Atrial Natriuretic Factor. In: Endocrinology and
Metabolism Clinics of North America. Philadelphia, PA: W. B. Saunders Company, 1987;16:1.
21. Jacobs JW, Vlasuk GP, Rosenblatt M. Atrial natriuretic factor receptors. In: Rosenblatt M,
Jacobs JW, eds, Endocrinology and Metabolism Clinics of North America. Philadelphia, PA: W. B. Saunders Company, 1987:63-77.
22. Blaine EH, Rosenblatt M. Atrial natriuretic factor: a hormone from the heart. In: McCann
SM, ed., Endocrinology: People and Ideas, American Physiological Society. 1988:397-419. 23. Rosenblatt M, Kronenberg MH, Potts JT Jr. Parathyroid hormone: physiology, chemistry,
biosynthesis, secretion, metabolism, and mode of action. In: DeGroot LJ, ed., Endocrinology, Vol. 2, 2nd ed. Philadelphia: W. B. Saunders Company, 1989:848-891.
42
24. Goldman ME, Rosenblatt M. Therapeutic potential for parathyroid hormone antagonists. Chapter 17. In: Magee PS, Henry DR, Block JH, eds., Probing Bioactive Mechanisms, Washington, D.C.: American Chemical Society, 1989:243-263.
25. Caulfield MP, Rosenblatt M. Condensation of: Lutropin-choriogonadotropin receptor: an
unusual member of the G protein-coupled receptor family. (McGarland KC, Sprengel R, Phillips HS, Kohler M, Rosemblit N, Nikolics K, Segaloff DL, Seeburg PH. Science 1989; 245:494). Chemtracts: Biochemistry and Molecular Biology 1990; 1:131-135.
26. Caulfield MP, Rosenblatt M. Condensation and commentary of: Identification by anti-idiotype
antibodies of an intracellular membrane protein that recognizes a mammalian endoplasma reticulum retention signal. (Vaux D, Tooze J, Fuller S. Nature 1990; 345:495). Chemtracts--Biochemistry and Molecular Biology 1990; 1:392-398.
27. Caulfield MP, Rosenblatt M. Parathyroid hormone-receptor interactions. Trends Endocrinol.
Metab. 1990; 1:164-168. 28. Rosenblatt M. From academia to industry: a mandate for drug discovery. Harvard Medical
Alumni Bulletin 1991; 65:47-51. 29. Strewler GJ, Rosenblatt M. "Mineral Metabolism". In: Felig P, Baxter JD, Broadus AE,
Frohman LA, eds., Endocrinology and Metabolism, Third Ed.,, New York: McGraw-Hill Book Co., 1995:1407-1516.
30. Chorev M, Rosenblatt M. Structure-function analysis of parathyroid hormone and parathyroid
hormone-related protein. The Parathyroids. New York: Raven Press, Ltd., 1994; 10:139-156. 31. Dresner-Pollak R, Rosenblatt M. Blockade of osteoclast-mediated bone resorption through
occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis. Journal of Cellular Biochemistry, 1994; 56:323-330.
32. Chorev M, Dresner-Pollak R, Eshel Y, Rosenblatt M. Approach to discovering novel
therapeutic agents for osteoporosis based on integrin receptor blockade. Biopolymers,1995; 37:367-375.
33. Chorev M, Bisello A, Behar V, Nakamoto C, Rosenblatt M, Maretto S, Mammi S, Peggion E.
Conformational Studies of Analogs of Parathyroid Hormone Related Protein (PTHrP) Containing Lactam-bridged Side-chains. Peptides: Chemistry, Structure and Biology, 1996; 217:525-526.
34. Chorev M and Rosenblatt M. Parathyroid Hormone: Structure Function Relations and
Analog Design. In: Bilezikian J, Raisz L, Rodan G, eds. Principles of Bone Biology. San Diego: Academic Press, 1996; 24:305-323.
35. Goldman L, Neill J, Rosenblatt M. The Business of Education: A New Paradigm. In: The
Physician Executive. March, 1997; 21-24. 36. Rosenblatt M, Rabkin T, Tosteson D. How One Teaching Hospital System and Medical
School are Jointly Affirming Their Academic Mission. Academic Medicine. 1997; 72:483-488.
43
37. Peggion E, Mammi S, Schievano E, Bisello A, Rosenblatt M, Chorev M. Conformational Studies of a Bicyclic Parathyroid Hormone-Related Protein-Derived Agonist. In: Peptides. August 1998; Proceedings of the 25th European Peptide Symposium, Budapest, pp. 378-379.
38. Bitan G, Scheibler L, Teng H, Rosenblatt M, Chorev M. Probing the Integrin avb3-Ligand
Bimolecular Interaction. Design and Evaluation of Benzophenone-containing Conformationally Constrained Ligands. In: Peptides. August 1998; Proceedings of the 25th European Peptide Symposium, Budapest, pp. 564-565.
39. Stoch, SA, Chorev, M, Rosenblatt, M. New Approaches to Osteoporosis Therapeutics. In:
Osteoporosis 2nd Edition, 2001; Marcus R, Feldman R, and Kelsey, J, eds., Academic Press, San Diego, pp. 769-818.
40. Chorev, M., Alexander, J.M., and Rosenblatt, M. Interactions of Parathyroid Hormone and
Parathyroid-Hormone Related Protein with their Receptors. In: The Parathyroids 2nd Edition, 2001; Bilezikian J P, Marcus R, and Levine M A, eds, Academic Press, pp. 53-91.
41. Chorev M, Rosenblatt, M. Parathyroid hormone-receptor interactions. In: Principles of Bone
Biology, 2nd Edition, 2001; Bilezikian, J P, Raisz L G, Rodan G A, eds. San Diego: Academic Press, pp. 423-461.
42. Peggion E, Mammi S, Schievano E, Silvestri L, Scheibler L, Rosenblatt M, Chorev M.
Structure-function relationship studies of analogs of the N-terminal 1-34 fragment of parathyroid hormone PTH containing b-alanine residues. Peptides 2000; Proceedings of the 26 European Peptide Symposium, Martinez J, Fehrentz J-A, eds. Editions EDK, Paris, pp. 711-712.
43. Dresner-Pollak R, Stoch SA, Rosenblatt M. New Approaches to Osteoporosis Therapeutics.
Osteoporosis (third edition), 2007; Marcus, Feldman, Nelson and Rosen, eds. Academic Press, pp. 1837-1895.
44. Wittelsberger A, Rosenblatt M. Parathyroid hormone-receptor interactions. (Chapter 29) In:
Principles of Bone Biology, 3rd Edition, (In Press); Bilezikian, J P, Raisz L G, Rodan G A, eds. San Diego: Academic Press
45. Rosenblatt M. When two keys fit one lock, surprises follow. Nature Chemical Biology. 2009;
5(10):707-708.
Related Documents
